{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":2464,"total_is_capped":false,"direct_labels_cover":16,"predictions_cover":2464,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"f6b61b014da0","filters":{"topic":"Lung Cancer Treatments and Mutations"}},"results":[{"id":"W2180481128","doi":"10.1038/nature13385","title":"Comprehensive molecular profiling of lung adenocarcinoma","year":2014,"lang":"en","type":"article","venue":"Nature","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5830,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; National Human Genome Research Institute; Howard Hughes Medical Institute","keywords":"Biology; Exon; Adenocarcinoma; Somatic cell; Alternative splicing; Lung cancer; KRAS; RNA splicing; Cancer research; Germline mutation; Messenger RNA; Genetics; Gene; Oncogene; Mutation; Molecular biology; Cancer; RNA; Medicine; Pathology; Cell cycle","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.006625504655281512,"gpt":0.3152565461208155,"spread":0.308631041465534,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001521559,0.0002068628,0.0002664398,0.001295332,0.0001868784,0.0002639116,0.0001398075,0.0001630041,0.0006443713],"category_scores_gemma":[0.0002229531,0.00008308676,0.0002280637,0.0007275562,0.00008008534,0.00009930848,0.0002402797,0.0001687538,0.0003603825],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001857418,"about_ca_system_score_gemma":0.0001755208,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001479568,"about_ca_topic_score_gemma":0.002940719,"domain_scores_codex":[0.9997869,0.00001824178,0.00001156761,0.00005460373,0.00009574209,0.00003300904],"domain_scores_gemma":[0.9998986,0.00001451079,0.00001925614,0.000009838346,0.00003405475,0.00002372499],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0001760758,0.00001876493,0.03393448,0.0001309723,0.00009042358,0.0003015965,0.00004986136,0.0002672255,0.9384274,0.00006406509,0.0005006234,0.02603858],"study_design_scores_gemma":[0.00001354465,0.0004141256,0.7067593,0.00002405985,0.0001976505,0.005652159,0.0001340344,0.002037669,0.270115,0.0001803659,0.01444771,0.00002422382],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9681764,0.01009008,0.008140834,0.0001699051,0.00001952839,0.00006147532,0.01022391,0.000412591,0.002705437],"genre_scores_gemma":[0.9615777,0.004552316,0.01205922,0.0001826336,0.00002215971,0.00007824021,0.01852898,0.00006174059,0.002937053],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001479568,"threshold_uncertainty_score":0.002941906,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2138297714","doi":"10.1056/nejmoa050753","title":"Erlotinib in Previously Treated Non–Small-Cell Lung Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5451,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research; Hotel Dieu Shaver Health and Rehabilitation Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; McGill University","funders":"National Cancer Institute","keywords":"Erlotinib; Medicine; Lung cancer; Hazard ratio; Internal medicine; Erlotinib Hydrochloride; Chemotherapy; Randomization; Placebo; Performance status; Oncology; Surgery; Epidermal growth factor receptor; Gastroenterology; Cancer; Randomized controlled trial; Confidence interval; Pathology","authors":[{"name":"Frances A. Shepherd","is_ca":true},{"name":"José Rodrigues Pereira","is_ca":false},{"name":"Tudor–Eliade Ciuleanu","is_ca":false},{"name":"Eng Huat Tan","is_ca":false},{"name":"Vera Hirsh","is_ca":true},{"name":"Sumitra Thongprasert","is_ca":false},{"name":"Daniel de Castro","is_ca":false},{"name":"Savitree Maoleekoonpiroj","is_ca":false},{"name":"Michael Smylie","is_ca":false},{"name":"Renato Martins","is_ca":false},{"name":"Maximiliano Van Kooten","is_ca":false},{"name":"Mircea Dediu","is_ca":false},{"name":"B. Findlay","is_ca":true},{"name":"Dongsheng Tu","is_ca":true},{"name":"D. Johnston","is_ca":true},{"name":"Andrea Bezjak","is_ca":true},{"name":"Gary M. Clark","is_ca":false},{"name":"P. Santabárbara","is_ca":false},{"name":"Lesley Seymour","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0143240950170995,"gpt":0.3292720035477968,"spread":0.3149479085306973,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001564731,0.0008176456,0.002081135,0.0002671011,0.0003267054,0.000614015,0.0005918209,0.001308154,0.003396596],"category_scores_gemma":[0.001301141,0.0003572507,0.001059297,0.0003326617,0.0005284552,0.0004998573,0.0002039807,0.00152324,0.0004626358],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005273804,"about_ca_system_score_gemma":0.0006990557,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004659313,"about_ca_topic_score_gemma":0.001289473,"domain_scores_codex":[0.9994708,0.0002806942,0.00005172531,0.00007735207,0.00004146914,0.00007808219],"domain_scores_gemma":[0.9992796,0.0002225565,0.0002282566,0.00003927449,0.00003839138,0.0001919739],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9390022,0.006104268,0.002528472,0.001596655,0.001338036,0.0001162314,0.00004144065,0.0004428737,0.006364977,0.0001146493,0.0009383695,0.0414119],"study_design_scores_gemma":[0.8981438,0.09216926,0.006386022,0.00007977611,0.0006051884,0.0001205821,0.00001250502,0.0004535028,0.0008373643,0.00007227352,0.001108607,0.00001119938],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807701,0.01493134,0.0002826915,0.0005490771,0.0006099693,0.001053439,0.0004026567,0.0000845749,0.001316188],"genre_scores_gemma":[0.9925235,0.003967998,0.0003647755,0.0005549641,0.0004822918,0.000878067,0.0003760167,0.000006092938,0.0008463775],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003396596,"threshold_uncertainty_score":0.01136273,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2002937040","doi":"10.1371/journal.pmed.0020073","title":"Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain","year":2005,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3526,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Washington University in St. Louis; Genentech; AstraZeneca; LUNGevity Foundation; Memorial Sloan-Kettering Cancer Center; CHEST Foundation; Canadian Institutes of Health Research; American Cancer Society","keywords":"Gefitinib; Erlotinib; T790M; Cancer research; Epidermal growth factor receptor; Lung cancer; Resistance mutation; Medicine; Mutation; Erlotinib Hydrochloride; Tyrosine kinase; Tyrosine-kinase inhibitor; Biology; Cancer; Oncology; Internal medicine; Genetics; Receptor","authors":[{"name":"William Pao","is_ca":false},{"name":"Vincent A. Miller","is_ca":false},{"name":"Katerina Politi","is_ca":false},{"name":"Gregory J. Riely","is_ca":false},{"name":"Romel Somwar","is_ca":false},{"name":"Maureen F. Zakowski","is_ca":false},{"name":"Mark G. Kris","is_ca":false},{"name":"Harold Varmus","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02397308457094872,"gpt":0.3131054173142422,"spread":0.2891323327432935,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000164093,0.0002965828,0.0002671235,0.0002760531,0.0002540222,0.0002724581,0.0002522921,0.0004597965,0.001484509],"category_scores_gemma":[0.0006550774,0.0000923577,0.0002556081,0.0001871441,0.0002525017,0.0001306678,0.0001913674,0.0003367739,0.0002661922],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003630186,"about_ca_system_score_gemma":0.0002306617,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004767694,"about_ca_topic_score_gemma":0.0007947451,"domain_scores_codex":[0.9998302,0.00001734514,0.0000251662,0.0000452514,0.00004569177,0.00003631783],"domain_scores_gemma":[0.9996191,0.00007130273,0.0001380056,0.00002434023,0.00004833758,0.00009886186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001477603,0.000409708,0.6319259,0.0002683172,0.0001867756,0.03221686,0.0003003497,0.0005687736,0.3026921,0.0002168362,0.0005965678,0.02914026],"study_design_scores_gemma":[0.0001985777,0.002614668,0.6674749,0.00002812357,0.0002113912,0.2595544,0.000147666,0.001537243,0.06511209,0.0001093202,0.002991286,0.00002032866],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9988116,0.0003116082,0.0001984032,0.00003433441,0.000003120052,0.000007850275,0.00003695584,0.00001315687,0.0005829762],"genre_scores_gemma":[0.999522,0.00006604558,0.0001604102,0.00001752165,0.000006879673,0.000003447579,0.00008196609,0.000002064451,0.0001395959],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001484509,"threshold_uncertainty_score":0.004966199,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2560717039","doi":"10.1056/nejmoa1612674","title":"Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3329,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK","keywords":"Osimertinib; T790M; Pemetrexed; Lung cancer; Medicine; Epidermal growth factor receptor; Oncology; Tyrosine-kinase inhibitor; Tyrosine kinase; Internal medicine; Cancer research; Chemotherapy; Cancer; Receptor; Erlotinib; Gefitinib; Cisplatin","authors":[{"name":"Tony Mok","is_ca":false},{"name":"Yi‐Long Wu","is_ca":false},{"name":"Myung‐Ju Ahn","is_ca":false},{"name":"Marina Chiara Garassino","is_ca":false},{"name":"Hye Ryun Kim","is_ca":false},{"name":"Suresh S. Ramalingam","is_ca":false},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Yong He","is_ca":false},{"name":"Hiroaki Akamatsu","is_ca":false},{"name":"Willemijn S.M.E. Theelen","is_ca":false},{"name":"Chee Khoon Lee","is_ca":false},{"name":"Martin Sebastian","is_ca":false},{"name":"Alison Templeton","is_ca":false},{"name":"Helen Mann","is_ca":false},{"name":"Marcelo Marotti","is_ca":false},{"name":"Serban Ghiorghiu","is_ca":false},{"name":"Vassiliki A. Papadimitrakopoulou","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01813295790068458,"gpt":0.3557524786313276,"spread":0.3376195207306431,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001286827,0.000412137,0.001201824,0.0001857283,0.0002043582,0.0003827167,0.0003398095,0.000610714,0.003580995],"category_scores_gemma":[0.0008247945,0.0001598261,0.0008352208,0.0002161934,0.0003964552,0.0003227656,0.0002224134,0.0009544829,0.000288825],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004231895,"about_ca_system_score_gemma":0.0007047662,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003557167,"about_ca_topic_score_gemma":0.0009779428,"domain_scores_codex":[0.9996106,0.0002155227,0.00003093213,0.0000501608,0.00002520169,0.00006759827],"domain_scores_gemma":[0.9994757,0.0002148489,0.0001204458,0.0000216776,0.00001363459,0.0001538513],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8975212,0.005489537,0.005272346,0.0009741485,0.0007692078,0.0001322217,0.00007833619,0.001335338,0.00883997,0.0002918156,0.001558911,0.07773703],"study_design_scores_gemma":[0.6681405,0.2984791,0.01739727,0.0001759827,0.001169278,0.0004135012,0.00006675264,0.001771485,0.005662452,0.0006939465,0.006007196,0.00002257397],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921331,0.003922001,0.0005059987,0.0003585881,0.0001845308,0.0007677682,0.0002438024,0.00003176925,0.001852503],"genre_scores_gemma":[0.9963527,0.001464141,0.0004036548,0.000290114,0.0001295415,0.0004828142,0.0002224593,0.000005731977,0.0006488969],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003580995,"threshold_uncertainty_score":0.01197958,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2990041408","doi":"10.1056/nejmoa1913662","title":"Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2816,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"William Osler Health System; University of Toronto","funders":"AstraZeneca","keywords":"Osimertinib; T790M; Medicine; Oncology; Epidermal growth factor receptor; Lung cancer; Gefitinib; Internal medicine; Hazard ratio; Progression-free survival; Tyrosine kinase; Cancer research; Overall survival; Cancer; Erlotinib; Receptor; Confidence interval","authors":[{"name":"Suresh S. Ramalingam","is_ca":false},{"name":"Johan Vansteenkiste","is_ca":false},{"name":"David Planchard","is_ca":false},{"name":"Byoung Chul Cho","is_ca":false},{"name":"Jhanelle E. Gray","is_ca":false},{"name":"Yuichiro Ohe","is_ca":false},{"name":"Caicun Zhou","is_ca":false},{"name":"Thanyanan Reungwetwattana","is_ca":false},{"name":"Ying Cheng","is_ca":false},{"name":"Busyamas Chewaskulyong","is_ca":false},{"name":"Riyaz Shah","is_ca":false},{"name":"Manuel Cobo","is_ca":false},{"name":"Ki Hyeong Lee","is_ca":false},{"name":"Parneet Cheema","is_ca":true},{"name":"Marcello Tiseo","is_ca":false},{"name":"Thomas John","is_ca":false},{"name":"Meng‐Chih Lin","is_ca":false},{"name":"Fumio Imamura","is_ca":false},{"name":"Takayasu Kurata","is_ca":false},{"name":"Alexander Todd","is_ca":false},{"name":"Rachel Hodge","is_ca":false},{"name":"Matilde Saggese","is_ca":false},{"name":"Yuri Rukazenkov","is_ca":false},{"name":"Jean‐Charles Soria","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.008928424385361516,"gpt":0.2917111297997033,"spread":0.2827827054143418,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00189186,0.0004790428,0.001128401,0.000334845,0.0001927451,0.0005122044,0.0004128735,0.000655996,0.001640473],"category_scores_gemma":[0.001579564,0.0001810559,0.001437646,0.0002970205,0.0005390846,0.0005800408,0.000358921,0.001121238,0.000137412],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008118345,"about_ca_system_score_gemma":0.0005729811,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005542331,"about_ca_topic_score_gemma":0.0009228267,"domain_scores_codex":[0.9993474,0.0003379526,0.00005340383,0.0001046112,0.00007002871,0.00008659077],"domain_scores_gemma":[0.9992478,0.0002316683,0.0002097986,0.00003551857,0.00002813276,0.0002470722],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8885818,0.005874343,0.0170587,0.0006406592,0.001468018,0.0001460061,0.000146728,0.004655515,0.007060477,0.0002116475,0.00119238,0.07296367],"study_design_scores_gemma":[0.2872429,0.6021781,0.09664608,0.0001820796,0.002627028,0.0003498121,0.0001032033,0.003895603,0.003113823,0.0008823638,0.002729761,0.0000493216],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968001,0.002025023,0.0001213735,0.0001210484,0.00007231355,0.00009730693,0.0001452895,0.000009402757,0.0006081609],"genre_scores_gemma":[0.9983406,0.0007550159,0.00009422038,0.0001277155,0.00007834307,0.0001279928,0.0002671157,0.00000283172,0.0002062953],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00189186,"threshold_uncertainty_score":0.01000524,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2134667653","doi":"10.1200/jco.2004.08.163","title":"Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2433,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Docetaxel; Pemetrexed; Neutropenia; Internal medicine; Lung cancer; Febrile neutropenia; Chemotherapy; Regimen; Dexamethasone; Chemotherapy regimen; Gastroenterology; Phases of clinical research; Oncology; Surgery; Cisplatin","authors":[{"name":"Nasser H. Hanna","is_ca":true},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Frank V. Fossella","is_ca":true},{"name":"Jose R. Pereira","is_ca":true},{"name":"Filippo de Marinis","is_ca":true},{"name":"Joachim von Pawel","is_ca":true},{"name":"U. Gatzemeier","is_ca":true},{"name":"Thomas Chang Yao Tsao","is_ca":true},{"name":"Miklos Pless","is_ca":true},{"name":"Thomas Müller","is_ca":true},{"name":"Hong-Liang Lim","is_ca":true},{"name":"Christopher E. Desch","is_ca":true},{"name":"Klára Szondy","is_ca":true},{"name":"Radj Gervais","is_ca":true},{"name":"Shaharyar","is_ca":false},{"name":"Christian Manegold","is_ca":true},{"name":"Sofia Paul","is_ca":true},{"name":"Paolo Paoletti","is_ca":true},{"name":"Lawrence Einhorn","is_ca":true},{"name":"Paul A. Bunn","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04615425508884495,"gpt":0.4591494644487017,"spread":0.4129952093598567,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001968741,0.001310727,0.00312402,0.0003221378,0.0004210578,0.00108935,0.0009420526,0.001388888,0.006109369],"category_scores_gemma":[0.002451515,0.000562157,0.001408646,0.0004018697,0.001161486,0.000768688,0.0003650796,0.003487931,0.0008884273],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00121542,"about_ca_system_score_gemma":0.001676932,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001340627,"about_ca_topic_score_gemma":0.003910386,"domain_scores_codex":[0.9992388,0.0004827712,0.00004236995,0.00008993032,0.00004835709,0.00009771642],"domain_scores_gemma":[0.9986021,0.0004308763,0.0003281351,0.00007835119,0.00006552789,0.0004950899],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9799119,0.006102925,0.0006539093,0.0002953559,0.0006209585,0.00003526683,0.00004164692,0.0004147287,0.00125871,0.0000875375,0.0007849089,0.009792116],"study_design_scores_gemma":[0.954416,0.04315466,0.001101837,0.00001902607,0.0001642248,0.00002685776,0.00001194811,0.000374937,0.0001596432,0.00007647184,0.0004892893,0.00000513953],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837309,0.004631059,0.0006156828,0.001130142,0.001003537,0.005531143,0.0009456283,0.0001082164,0.002303592],"genre_scores_gemma":[0.9843363,0.002566028,0.001246986,0.001644026,0.0004581412,0.0057751,0.001057122,0.0000210005,0.002895429],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006109369,"threshold_uncertainty_score":0.02043784,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2373606074","doi":"10.1016/j.ejca.2016.03.081","title":"RECIST 1.1—Update and clarification: From the RECIST committee","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1894,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"Canadian Cancer Society Research Institute; National Cancer Institute; National Cancer Research Institute","keywords":"Response Evaluation Criteria in Solid Tumors; Medicine; Medical physics; Radiology; Disease; Progressive disease; Internal medicine","authors":[{"name":"Lawrence H. Schwartz","is_ca":false},{"name":"Saskia Litière","is_ca":false},{"name":"Elisabeth G.E. de Vries","is_ca":false},{"name":"Robert Ford","is_ca":false},{"name":"Stephen J. Gwyther","is_ca":false},{"name":"Sumithra J. Mandrekar","is_ca":false},{"name":"Lalitha Shankar","is_ca":false},{"name":"Jan Bogaerts","is_ca":false},{"name":"Alice P. Chen","is_ca":false},{"name":"Janet Dancey","is_ca":true},{"name":"Wendy Hayes","is_ca":false},{"name":"F. Stephen Hodi","is_ca":false},{"name":"Otto S. Hoekstra","is_ca":false},{"name":"Erich P. Huang","is_ca":false},{"name":"Nancy U. Lin","is_ca":false},{"name":"Yan Liu","is_ca":false},{"name":"Patrick Therasse","is_ca":false},{"name":"Jedd D. Wolchok","is_ca":false},{"name":"Lesley Seymour","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02242408296974398,"gpt":0.3170312627307039,"spread":0.29460717976096,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.09814455,0.003035703,0.008738166,0.007820195,0.00239106,0.01106267,0.01493088,0.02487615,0.007024104],"category_scores_gemma":[0.2352228,0.002366528,0.007170045,0.007744217,0.003336719,0.007541193,0.006295069,0.03924045,0.01567969],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01000464,"about_ca_system_score_gemma":0.02522342,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01227914,"about_ca_topic_score_gemma":0.01573748,"domain_scores_codex":[0.9373983,0.02330245,0.01703479,0.002970798,0.0162228,0.003070893],"domain_scores_gemma":[0.7640466,0.07638548,0.02820551,0.01157168,0.1072315,0.01255926],"domain_codex":null,"domain_gemma":"methods","domain_candidate":"methods","domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001652824,0.00002603053,0.0004323466,0.0008939922,0.00009975143,0.00004797587,0.00005409578,0.0003919172,0.00009286158,0.001441885,0.9565123,0.03984155],"study_design_scores_gemma":[0.0002622035,0.00008035888,0.001831378,0.006261714,0.0003630585,0.0003546694,0.00007434739,0.0005071838,0.0003993631,0.003399364,0.9863173,0.0001490619],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.00124814,0.08235671,0.01159908,0.7818219,0.09008524,0.001094881,0.006177366,0.001908742,0.02370798],"genre_scores_gemma":[0.01243638,0.07233162,0.05409919,0.6891133,0.1230842,0.004378783,0.02071284,0.003704285,0.02013944],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.9018555,"threshold_uncertainty_score":0.5190442,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1970476748","doi":"10.1056/nejmoa050736","title":"Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1854,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; University of Ottawa; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Erlotinib; Medicine; Lung cancer; Epidermal growth factor receptor; Oncology; Internal medicine; Clinical trial; Erlotinib Hydrochloride; Placebo; Cancer; Pathology","authors":[{"name":"Ming‐Sound Tsao","is_ca":true},{"name":"Akira Sakurada","is_ca":true},{"name":"Jean-Claude Cutz","is_ca":true},{"name":"Chang‐Qi Zhu","is_ca":true},{"name":"Suzanne Kamel‐Reid","is_ca":true},{"name":"Jeremy A. Squire","is_ca":true},{"name":"Ian Lorimer","is_ca":true},{"name":"Tong Zhang","is_ca":true},{"name":"Geoffrey Liu","is_ca":true},{"name":"Manijeh Daneshmand","is_ca":true},{"name":"Paula Marrano","is_ca":true},{"name":"Gilda da Cunha Santos","is_ca":true},{"name":"Alain E. Lagarde","is_ca":true},{"name":"Frank C. Richardson","is_ca":false},{"name":"Lesley Seymour","is_ca":true},{"name":"Marlo Whitehead","is_ca":true},{"name":"Keyue Ding","is_ca":true},{"name":"Joseph L. Pater","is_ca":true},{"name":"Frances A. Shepherd","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02248944063098263,"gpt":0.4079720786852618,"spread":0.3854826380542792,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001158932,0.0002227404,0.0005000977,0.0002388203,0.0001767251,0.0004043612,0.0001630427,0.0004933841,0.001087642],"category_scores_gemma":[0.001479744,0.00006165566,0.0003802727,0.0002995581,0.0001582964,0.0001915432,0.0001437593,0.0004964702,0.0001771146],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003543868,"about_ca_system_score_gemma":0.0002446906,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003517081,"about_ca_topic_score_gemma":0.0006837926,"domain_scores_codex":[0.9996706,0.0001212143,0.00003166026,0.00005493677,0.00006643788,0.0000549968],"domain_scores_gemma":[0.9988099,0.0004350278,0.000427676,0.00002710156,0.00008315179,0.0002171956],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04272109,0.0007777387,0.8965794,0.000359191,0.0008816413,0.0002106657,0.00003670057,0.001247121,0.003519443,0.00008418391,0.001434387,0.05214846],"study_design_scores_gemma":[0.002106865,0.006916264,0.9848602,0.0000683988,0.0007935115,0.0005607484,0.00003782639,0.002095545,0.001110147,0.0002068436,0.001232074,0.00001165188],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994652,0.004107075,0.00007375563,0.0002922223,0.00002728719,0.00001825098,0.0002495828,0.000006612147,0.0005732244],"genre_scores_gemma":[0.9990925,0.0003865347,0.00003861469,0.00004870246,0.00005048495,0.000009457767,0.0002597131,6.180916e-7,0.0001133442],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001158932,"threshold_uncertainty_score":0.006129146,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2127342594","doi":"10.1056/nejmoa043623","title":"Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1832,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Vinorelbine; Internal medicine; Neutropenia; Lung cancer; Gastroenterology; Surgery; Hazard ratio; Chemotherapy; Regimen; Cisplatin; Confidence interval","authors":[{"name":"Timothy Winton","is_ca":true},{"name":"Robert B. Livingston","is_ca":false},{"name":"David C. Johnson","is_ca":false},{"name":"James R. Rigas","is_ca":false},{"name":"Michael Johnston","is_ca":true},{"name":"Charles Butts","is_ca":true},{"name":"Yvon Cormier","is_ca":true},{"name":"Richard Inculet","is_ca":true},{"name":"Eric Vallières","is_ca":false},{"name":"Willard A. Fry","is_ca":false},{"name":"Drew Bethune","is_ca":true},{"name":"Joseph Ayoub","is_ca":true},{"name":"Keyue Ding","is_ca":true},{"name":"Lesley Seymour","is_ca":true},{"name":"Barbara Graham","is_ca":true},{"name":"Ming‐Sound Tsao","is_ca":true},{"name":"David R. Gandara","is_ca":false},{"name":"Kenneth A. Kesler","is_ca":false},{"name":"Todd L. Demmy","is_ca":false},{"name":"Frances A. Shepherd","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02142726019502914,"gpt":0.3306539613456979,"spread":0.3092267011506687,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009288688,0.0002949003,0.0007409719,0.000198656,0.0001544445,0.0002528165,0.0002660998,0.0002944489,0.001209145],"category_scores_gemma":[0.001276796,0.0001383823,0.0005631007,0.0001570641,0.0003240847,0.0002516682,0.0001955874,0.0005673717,0.0001205709],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004997391,"about_ca_system_score_gemma":0.0006662053,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005647156,"about_ca_topic_score_gemma":0.00172181,"domain_scores_codex":[0.9996185,0.0002063572,0.00003671279,0.00004873674,0.00003211202,0.00005758875],"domain_scores_gemma":[0.9991788,0.0003513661,0.0001405423,0.00004307581,0.00002530761,0.0002609663],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8205745,0.01147435,0.02205345,0.000483059,0.0007035442,0.0001938647,0.0001631594,0.004515966,0.01681414,0.0001559345,0.0004719172,0.1223962],"study_design_scores_gemma":[0.1339469,0.7518438,0.1009114,0.00008282767,0.001039779,0.0003628717,0.0001236756,0.004337253,0.004910137,0.0003720937,0.002034087,0.00003514791],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.999119,0.0004985863,0.00008351366,0.00004783066,0.00003071651,0.00007607973,0.00002660334,0.000003204524,0.0001144694],"genre_scores_gemma":[0.999226,0.0002782099,0.0001550308,0.00005228286,0.00002443366,0.00008185551,0.00004989689,8.433935e-7,0.0001315491],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001209145,"threshold_uncertainty_score":0.004912376,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2042386784","doi":"10.1016/j.cell.2012.08.029","title":"Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing","year":2012,"lang":"en","type":"article","venue":"Cell","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1826,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; National Human Genome Research Institute; Canadian Institutes of Health Research; National Institute of General Medical Sciences; Broad Institute","keywords":"Biology; Adenocarcinoma; Exome sequencing; Genetics; Gene; Lung cancer; Mutation; Exome; Somatic cell; Context (archaeology); ARID1A; Germline mutation; Cancer research; Cancer; Pathology","authors":[{"name":"Marcin Imieliński","is_ca":false},{"name":"Alice H. Berger","is_ca":false},{"name":"Peter S. Hammerman","is_ca":false},{"name":"Bryan Hernandez","is_ca":false},{"name":"Trevor J. Pugh","is_ca":false},{"name":"Eran Hodis","is_ca":false},{"name":"Jeonghee Cho","is_ca":false},{"name":"James Suh","is_ca":false},{"name":"Marzia Capelletti","is_ca":false},{"name":"Andrey Sivachenko","is_ca":false},{"name":"Carrie Sougnez","is_ca":false},{"name":"Daniel Auclair","is_ca":false},{"name":"Michael S. Lawrence","is_ca":false},{"name":"Petar Stojanov","is_ca":false},{"name":"Kristian Cibulskis","is_ca":false},{"name":"Kyusam Choi","is_ca":false},{"name":"Luc de Waal","is_ca":false},{"name":"Tanaz Sharifnia","is_ca":false},{"name":"Angela N. Brooks","is_ca":false},{"name":"Heidi Greulich","is_ca":false},{"name":"Shantanu Banerji","is_ca":false},{"name":"Thomas Zander","is_ca":false},{"name":"Danila Seidel","is_ca":false},{"name":"Frauke Leenders","is_ca":false},{"name":"Sascha Ansén","is_ca":false},{"name":"Corinna Ludwig","is_ca":false},{"name":"Walburga Engel-Riedel","is_ca":false},{"name":"Erich Stoelben","is_ca":false},{"name":"Jürgen Wolf","is_ca":false},{"name":"Chandra Goparju","is_ca":false},{"name":"Kristin Thompson","is_ca":false},{"name":"Wendy Winckler","is_ca":false},{"name":"David J. Kwiatkowski","is_ca":false},{"name":"Bruce E. Johnson","is_ca":false},{"name":"Pasi A. Jänne","is_ca":false},{"name":"Vincent A. Miller","is_ca":false},{"name":"William Pao","is_ca":false},{"name":"William D. Travis","is_ca":false},{"name":"Harvey I. Pass","is_ca":false},{"name":"Stacey Gabriel","is_ca":false},{"name":"Eric S. Lander","is_ca":false},{"name":"Roman K. Thomas","is_ca":false},{"name":"Levi A. Garraway","is_ca":false},{"name":"Gad Getz","is_ca":false},{"name":"Matthew Meyerson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02714034130342818,"gpt":0.2718057737046342,"spread":0.244665432401206,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008011127,0.0004155296,0.0005902928,0.00130446,0.0004182758,0.0009906348,0.0004630498,0.0007649897,0.0008444464],"category_scores_gemma":[0.002130795,0.0003682387,0.000441626,0.0007547375,0.0003793827,0.0004042778,0.0006153284,0.001021714,0.0002762856],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005373092,"about_ca_system_score_gemma":0.000438859,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002156535,"about_ca_topic_score_gemma":0.005342341,"domain_scores_codex":[0.9995151,0.00007910102,0.00003462384,0.000133325,0.0001930723,0.0000448179],"domain_scores_gemma":[0.9992784,0.0002545752,0.000169699,0.0001181924,0.0001142181,0.00006491033],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0008265179,0.0001466536,0.1192539,0.0005518915,0.000660878,0.001239826,0.0002912132,0.01440371,0.6735979,0.004506165,0.005814387,0.1787069],"study_design_scores_gemma":[0.0002279603,0.0006566743,0.3625248,0.0002353226,0.001013983,0.007230856,0.0005943799,0.1260766,0.4133933,0.03990062,0.0479793,0.0001663044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8724864,0.007689054,0.1022265,0.002353624,0.0002142756,0.0002221744,0.007677345,0.0015478,0.005582897],"genre_scores_gemma":[0.9144837,0.001849783,0.07807195,0.0008793206,0.00006808501,0.0001010225,0.002826229,0.0001990737,0.001520903],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002156535,"threshold_uncertainty_score":0.004288018,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3172081492","doi":"10.1056/nejmoa2103695","title":"Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1769,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Amgen","keywords":"KRAS; Medicine; Lung cancer; Mutation; Lung; Cancer research; Internal medicine; Oncology; Cancer; Biology; Genetics; Colorectal cancer; Gene","authors":[{"name":"Ferdinandos Skoulidis","is_ca":false},{"name":"Bob T. Li","is_ca":false},{"name":"Grace K. Dy","is_ca":false},{"name":"Timothy Price","is_ca":false},{"name":"Gerald S. Falchook","is_ca":false},{"name":"Jürgen Wolf","is_ca":false},{"name":"Antoîne Italiano","is_ca":false},{"name":"Martin Schüler","is_ca":false},{"name":"Hossein Borghaei","is_ca":false},{"name":"Fabrice Barlési","is_ca":false},{"name":"Terufumi Kato","is_ca":false},{"name":"Alessandra Curioni‐Fontecedro","is_ca":false},{"name":"Adrian G. Sacher","is_ca":true},{"name":"Alexander I. Spira","is_ca":false},{"name":"Suresh S. Ramalingam","is_ca":false},{"name":"Toshiaki Takahashi","is_ca":false},{"name":"Benjamin Besse","is_ca":false},{"name":"Abraham Anderson","is_ca":false},{"name":"Agnes Ang","is_ca":false},{"name":"Qui Tran","is_ca":false},{"name":"Omar Mather","is_ca":false},{"name":"Haby Henary","is_ca":false},{"name":"Gataree Ngarmchamnanrith","is_ca":false},{"name":"Gregory Friberg","is_ca":false},{"name":"Vamsidhar Velcheti","is_ca":false},{"name":"Ramaswamy Govindan","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01351052059467178,"gpt":0.330700063136702,"spread":0.3171895425420302,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005765571,0.0003238117,0.0005084356,0.0003207768,0.000134917,0.0003718355,0.000203544,0.0003498386,0.002586788],"category_scores_gemma":[0.0003916044,0.00007935894,0.0004962424,0.0002912501,0.0002261401,0.0002536824,0.0001501861,0.0006357439,0.0004897],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004046801,"about_ca_system_score_gemma":0.0006124213,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003640465,"about_ca_topic_score_gemma":0.002032435,"domain_scores_codex":[0.9998473,0.0000652955,0.00001344154,0.00002671068,0.00002916488,0.00001803303],"domain_scores_gemma":[0.9997923,0.00005009113,0.00007810463,0.000009252655,0.00002325525,0.00004708598],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.09763154,0.002908661,0.02331595,0.007262185,0.002021597,0.001020464,0.0001724109,0.002455253,0.1016839,0.001067225,0.01916306,0.7412978],"study_design_scores_gemma":[0.151779,0.2996728,0.2421288,0.003239049,0.006660998,0.01286571,0.0003804654,0.006644149,0.09816899,0.002782585,0.1755104,0.0001669578],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8947292,0.080557,0.001362586,0.003455207,0.0003910014,0.001615289,0.002566879,0.0002035725,0.01511925],"genre_scores_gemma":[0.9709071,0.02012276,0.001927723,0.001522617,0.0001991484,0.0005018151,0.001963993,0.00001969395,0.002835153],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002586788,"threshold_uncertainty_score":0.008653641,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3087210493","doi":"10.1056/nejmoa2027071","title":"Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1756,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Chugai Pharmaceutical; EMD Serono; Genentech; Ono Pharmaceutical; Shionogi; Loxo Oncology; Astellas Pharma; Mirati Therapeutics; Daiichi Sankyo Europe; Sanofi; Halozyme; F. Hoffmann-La Roche; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Spectrum Pharmaceuticals; Amgen; Kyorin Pharmaceutical; Pfizer; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Osimertinib; Lung cancer; Medicine; Cancer research; Oncology; Internal medicine; Cancer; Epidermal growth factor receptor; Erlotinib","authors":[{"name":"Yi‐Long Wu","is_ca":false},{"name":"Masahiro Tsuboi","is_ca":false},{"name":"Jie He","is_ca":false},{"name":"Thomas John","is_ca":false},{"name":"Christian Grohé","is_ca":false},{"name":"Margarita Majem","is_ca":false},{"name":"Jonathan W. Goldman","is_ca":false},{"name":"К. К. Лактионов","is_ca":false},{"name":"Sang‐We Kim","is_ca":false},{"name":"Terufumi Kato","is_ca":false},{"name":"Huu-Vinh Vu","is_ca":false},{"name":"Shun Lü","is_ca":false},{"name":"Kye Young Lee","is_ca":false},{"name":"Charuwan Akewanlop","is_ca":false},{"name":"Chong‐Jen Yu","is_ca":false},{"name":"Filippo de Marinis","is_ca":false},{"name":"Laura Bonanno","is_ca":false},{"name":"Manuel Dómine","is_ca":false},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Lingmin Zeng","is_ca":false},{"name":"Rachel Hodge","is_ca":false},{"name":"Ajlan Atasoy","is_ca":false},{"name":"Yuri Rukazenkov","is_ca":false},{"name":"Roy S. Herbst","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02115782651282301,"gpt":0.3285523371855753,"spread":0.3073945106727523,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006185542,0.0003364139,0.000565009,0.0001205948,0.000146888,0.0002723875,0.0001598125,0.000276637,0.001125999],"category_scores_gemma":[0.0005036528,0.0001095081,0.0003889674,0.0001063703,0.0001632834,0.000191208,0.0001405044,0.0004731425,0.0001555792],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004579404,"about_ca_system_score_gemma":0.0004608609,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000363491,"about_ca_topic_score_gemma":0.0009895378,"domain_scores_codex":[0.999849,0.00006767819,0.00001521618,0.00001928563,0.00002065322,0.00002811996],"domain_scores_gemma":[0.9998372,0.00003561549,0.00005246303,0.000007837156,0.00001219483,0.00005476105],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4434836,0.007460885,0.0679066,0.001588857,0.001524862,0.001143961,0.0002791516,0.003441894,0.0489041,0.0005557709,0.007794605,0.4159157],"study_design_scores_gemma":[0.285185,0.4004923,0.2572469,0.0003892092,0.003067896,0.003666997,0.0002696904,0.006595837,0.02017008,0.001253721,0.02161057,0.00005205684],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951808,0.003345447,0.0001517756,0.0002800425,0.0001002753,0.0001257219,0.00007693754,0.00001401538,0.0007249884],"genre_scores_gemma":[0.9976676,0.001377307,0.0001621901,0.0001632702,0.00008016093,0.00009678314,0.0001041971,0.00000215177,0.0003463507],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001125999,"threshold_uncertainty_score":0.003766835,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2132870547","doi":"10.1016/s1470-2045(14)71173-8","title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1580,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"Boehringer Ingelheim","keywords":"Medicine; Afatinib; Pemetrexed; Lung cancer; Internal medicine; Adenocarcinoma; Lung; Gemcitabine; Chemotherapy; Population; Gastroenterology; Oncology; Cisplatin; Surgery; Gefitinib; Epidermal growth factor receptor; Cancer","authors":[{"name":"James Chih‐Hsin Yang","is_ca":false},{"name":"Yi‐Long Wu","is_ca":false},{"name":"Martin Schüler","is_ca":false},{"name":"Martin Sebastian","is_ca":false},{"name":"Sanjay Popat","is_ca":false},{"name":"Nobuyuki Yamamoto","is_ca":false},{"name":"Caicun Zhou","is_ca":false},{"name":"Cheng-Ping Hu","is_ca":false},{"name":"Kenneth J. O’Byrne","is_ca":false},{"name":"Jifeng Feng","is_ca":false},{"name":"Shun Lü","is_ca":false},{"name":"Yunchao Huang","is_ca":false},{"name":"Sarayut Lucien Geater","is_ca":false},{"name":"Kye Young Lee","is_ca":false},{"name":"Chun-Ming Tsai","is_ca":false},{"name":"В. А. Горбунова","is_ca":false},{"name":"Vera Hirsh","is_ca":true},{"name":"Jaafar Bennouna","is_ca":false},{"name":"С. В. Орлов","is_ca":false},{"name":"Tony Mok","is_ca":false},{"name":"Michael Boyer","is_ca":false},{"name":"Wu‐Chou Su","is_ca":false},{"name":"Ki Hyeong Lee","is_ca":false},{"name":"Terufumi Kato","is_ca":false},{"name":"Dan Massey","is_ca":false},{"name":"Mehdi Shahidi","is_ca":false},{"name":"Victoria Zazulina","is_ca":false},{"name":"Lecia V. Sequist","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1710050663165039,"gpt":0.4951860196022361,"spread":0.3241809532857323,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005279308,0.001518481,0.003908913,0.000515877,0.0003292905,0.001347054,0.001205662,0.001826663,0.003662114],"category_scores_gemma":[0.005747153,0.0005550613,0.006175588,0.0007252072,0.001506886,0.002081972,0.0006306953,0.004067939,0.0005296491],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001336337,"about_ca_system_score_gemma":0.0008760226,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001016939,"about_ca_topic_score_gemma":0.002956656,"domain_scores_codex":[0.9974962,0.001733726,0.000168221,0.0002662136,0.0001378231,0.000197769],"domain_scores_gemma":[0.9969276,0.001467396,0.0007643172,0.0002675264,0.0001156234,0.0004575949],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9632995,0.001149808,0.001006601,0.00145248,0.004647218,0.0000335134,0.00007780366,0.001240766,0.001405236,0.0001521305,0.0007252824,0.02480973],"study_design_scores_gemma":[0.9340686,0.05596494,0.003807032,0.0001143321,0.003269413,0.0001108563,0.0000555375,0.0006776191,0.0003682862,0.0005980806,0.0009255196,0.00003991018],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9690295,0.02401806,0.00103135,0.00112723,0.0004751954,0.001236202,0.001280729,0.00009717297,0.001704579],"genre_scores_gemma":[0.9885609,0.005931124,0.001204971,0.0007764235,0.0001888277,0.0008931204,0.001192931,0.00003383774,0.00121789],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005279308,"threshold_uncertainty_score":0.02791995,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3215921195","doi":"10.1016/j.jtho.2021.11.003","title":"The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015","year":2021,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1481,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute; BeiGene; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Grading (engineering); SMARCA4; Pathology; Immunohistochemistry; Lung; Adenoma; Internal medicine; Biology","authors":[{"name":"Andrew G. Nicholson","is_ca":false},{"name":"Ming‐Sound Tsao","is_ca":true},{"name":"Mary Beth Beasley","is_ca":false},{"name":"Alain Borczuk","is_ca":false},{"name":"Élisabeth Brambilla","is_ca":false},{"name":"Wendy A. Cooper","is_ca":false},{"name":"Sanja Đačić","is_ca":false},{"name":"Deepali Jain","is_ca":false},{"name":"Keith M. Kerr","is_ca":false},{"name":"Sylvie Lantuéjoul","is_ca":false},{"name":"Masayuki Noguchi","is_ca":false},{"name":"Mauro Papotti","is_ca":false},{"name":"Natasha Rekhtman","is_ca":false},{"name":"Giorgio V. Scagliotti","is_ca":false},{"name":"Paul Van Schil","is_ca":false},{"name":"Lynette M. Sholl","is_ca":false},{"name":"Yasushi Yatabe","is_ca":false},{"name":"Akihiko Yoshida","is_ca":false},{"name":"William D. Travis","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04722255255441719,"gpt":0.5551534797927689,"spread":0.5079309272383516,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009922156,0.0006791697,0.001427331,0.00198145,0.0001688277,0.001153494,0.0008078769,0.000886708,0.002941628],"category_scores_gemma":[0.001926639,0.000181285,0.001006709,0.002066162,0.0003470492,0.001052584,0.0005718455,0.001551246,0.001445045],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00108064,"about_ca_system_score_gemma":0.002576952,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003088737,"about_ca_topic_score_gemma":0.005349557,"domain_scores_codex":[0.9995947,0.00006783866,0.00007345161,0.00007753465,0.0001374128,0.00004914396],"domain_scores_gemma":[0.9989251,0.0004216896,0.0002006523,0.00001929418,0.0003501973,0.00008297394],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001067454,0.00002737056,0.0009944941,0.01056006,0.000180048,0.00007652085,0.00002176958,0.000416663,0.0005600771,0.001740165,0.04330331,0.9420129],"study_design_scores_gemma":[0.00003491672,0.0001159339,0.004783577,0.01037954,0.0005685969,0.0009501071,0.00006710084,0.0002014956,0.0003074546,0.001813074,0.9807425,0.00003580425],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000157456,0.9968051,0.0001503879,0.001182063,0.0004632632,0.000005446911,0.0001328211,0.00001127056,0.001092246],"genre_scores_gemma":[0.001480063,0.9958152,0.0003839158,0.001045092,0.0004708489,0.000006361104,0.0003037199,0.000004531662,0.0004902321],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003088737,"threshold_uncertainty_score":0.009840786,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1974903221","doi":"10.1056/nejmoa1311107","title":"Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1475,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Ceritinib; Crizotinib; Anaplastic lymphoma kinase; Medicine; ALK inhibitor; Internal medicine; Lung cancer; Oncology; Gastroenterology","authors":[{"name":"Alice T. Shaw","is_ca":false},{"name":"Dong-Wan Kim","is_ca":false},{"name":"Ranee Mehra","is_ca":false},{"name":"Daniel S.W. Tan","is_ca":false},{"name":"Enriqueta Felip","is_ca":false},{"name":"Laura Q.M. Chow","is_ca":false},{"name":"D. Ross Camidge","is_ca":false},{"name":"Johan Vansteenkiste","is_ca":false},{"name":"Sunil Sharma","is_ca":false},{"name":"Tommaso De Pas","is_ca":false},{"name":"Gregory J. Riely","is_ca":false},{"name":"Benjamin Solomon","is_ca":false},{"name":"Juergen Wolf","is_ca":false},{"name":"Michael Thomas","is_ca":false},{"name":"Martin Schüler","is_ca":false},{"name":"Geoffrey Liu","is_ca":true},{"name":"Armando Santoro","is_ca":false},{"name":"Yvonne Lau","is_ca":false},{"name":"Meredith A. Goldwasser","is_ca":false},{"name":"Anthony Boral","is_ca":false},{"name":"Jeffrey A. Engelman","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01245342306717361,"gpt":0.3153880680622122,"spread":0.3029346449950386,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000818208,0.0003865642,0.0009724481,0.0001769309,0.0002308421,0.0002979391,0.0003080434,0.0002975846,0.0005401591],"category_scores_gemma":[0.0005810531,0.0001068424,0.0003733684,0.0002052531,0.0002371713,0.0002486084,0.0002153657,0.0006827722,0.0001643165],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008948726,"about_ca_system_score_gemma":0.000804918,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001279116,"about_ca_topic_score_gemma":0.003265674,"domain_scores_codex":[0.9997392,0.0001019084,0.0000270821,0.00004598183,0.00003942156,0.00004631225],"domain_scores_gemma":[0.9996356,0.0001009669,0.0000856184,0.00001719888,0.00003594904,0.0001247066],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1155675,0.006498623,0.1739369,0.001680754,0.001011082,0.004356036,0.0004553849,0.01023001,0.1445909,0.0003849881,0.008303534,0.5329844],"study_design_scores_gemma":[0.06037739,0.2298332,0.5534681,0.0002202778,0.001919038,0.01593527,0.0002843324,0.01620309,0.08820224,0.0005741931,0.03288787,0.00009513358],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913397,0.006768006,0.0003376047,0.0003173206,0.00003966071,0.0001257955,0.00006196656,0.00003446446,0.000975445],"genre_scores_gemma":[0.9976197,0.001510651,0.0003042337,0.0001126249,0.00005132661,0.00003670072,0.0001520467,0.000005201021,0.0002073485],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001279116,"threshold_uncertainty_score":0.006492794,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1978236936","doi":"10.1097/jto.0b013e318290868f","title":"Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1284,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Guideline; Lung cancer; Tyrosine kinase; Oncology; Internal medicine; Cancer; Selection (genetic algorithm); Pathology; Receptor","authors":[{"name":"Neal I. Lindeman","is_ca":false},{"name":"Philip T. Cagle","is_ca":false},{"name":"Mary Beth Beasley","is_ca":false},{"name":"Dhananjay Chitale","is_ca":false},{"name":"Sanja Đačić","is_ca":false},{"name":"Giuseppe Giaccone","is_ca":false},{"name":"Robert B. Jenkins","is_ca":false},{"name":"David J. Kwiatkowski","is_ca":false},{"name":"Juan‐Sebastian Saldivar","is_ca":false},{"name":"Jeremy A. Squire","is_ca":true},{"name":"Erik Thunnissen","is_ca":false},{"name":"Marc Ladanyi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01468322786349575,"gpt":0.4181217731418935,"spread":0.4034385452783977,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004643064,0.001232818,0.002274023,0.003069323,0.001144534,0.001666223,0.005304073,0.007088319,0.003891093],"category_scores_gemma":[0.01127042,0.0007767691,0.003817182,0.001938992,0.0008212908,0.001404187,0.001408469,0.007316483,0.003912588],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002792735,"about_ca_system_score_gemma":0.008280839,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02689248,"about_ca_topic_score_gemma":0.0515787,"domain_scores_codex":[0.9958664,0.001061474,0.001181362,0.0002489778,0.0013644,0.0002773745],"domain_scores_gemma":[0.9857193,0.003039698,0.001328155,0.0002930829,0.008710064,0.0009097425],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009256899,0.000289003,0.008738188,0.0007440877,0.0001624861,0.000964609,0.000168615,0.001713573,0.002717011,0.002494602,0.8802773,0.1016379],"study_design_scores_gemma":[0.0005686324,0.0004071996,0.0750327,0.01051934,0.0009053498,0.008963224,0.0006062912,0.007322407,0.003850701,0.01389677,0.8777074,0.0002200468],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.02198633,0.1184134,0.1215867,0.5374235,0.01476885,0.007092538,0.04112364,0.004643885,0.1329611],"genre_scores_gemma":[0.1019432,0.09235633,0.364376,0.2721357,0.009644254,0.009041716,0.08808463,0.001164205,0.06125396],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.02689248,"threshold_uncertainty_score":0.05347192,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2122553809","doi":"10.1016/s0140-6736(08)61758-4","title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial","year":2008,"lang":"en","type":"article","venue":"The Lancet","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1243,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McGill University Health Centre","funders":"AstraZeneca","keywords":"Gefitinib; Docetaxel; Medicine; Lung cancer; Internal medicine; Regimen; Hazard ratio; Population; Oncology; Chemotherapy; Performance status; Cancer; Epidermal growth factor receptor; Confidence interval","authors":[{"name":"Edward S. Kim","is_ca":false},{"name":"Vera Hirsh","is_ca":true},{"name":"Tony Mok","is_ca":false},{"name":"Mark A. Socinski","is_ca":false},{"name":"Radj Gervais","is_ca":false},{"name":"Yi‐Long Wu","is_ca":false},{"name":"Long-Yun Li","is_ca":false},{"name":"Claire Watkins","is_ca":false},{"name":"Mark V. Sellers","is_ca":false},{"name":"Elizabeth Lowe","is_ca":false},{"name":"Yan Sun","is_ca":false},{"name":"Mei‐Lin Liao","is_ca":false},{"name":"Kell Østerlind","is_ca":false},{"name":"Martin Reck","is_ca":false},{"name":"Alison Armour","is_ca":false},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Scott M. Lippman","is_ca":false},{"name":"Jean‐Yves Douillard","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06467038308692118,"gpt":0.372727022308989,"spread":0.3080566392220678,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001296783,0.001533312,0.003027143,0.0003279787,0.0004042486,0.001096715,0.0007487686,0.002233933,0.006385579],"category_scores_gemma":[0.001323624,0.0006213697,0.002287428,0.0003383776,0.001116576,0.001119599,0.0003714102,0.003149287,0.0008994148],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001335002,"about_ca_system_score_gemma":0.0009684635,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002128748,"about_ca_topic_score_gemma":0.006032233,"domain_scores_codex":[0.9995345,0.0002172425,0.00002295445,0.00008765781,0.00002429213,0.0001133616],"domain_scores_gemma":[0.9993951,0.000195849,0.0001203224,0.00004544331,0.00002600105,0.0002172232],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9671026,0.002271886,0.0009358262,0.0009931676,0.001217018,0.0001025848,0.00007170861,0.0007812919,0.001654845,0.0002051726,0.002067207,0.02259683],"study_design_scores_gemma":[0.9596922,0.03555365,0.00200942,0.00005141105,0.0007149266,0.00008007362,0.0000286844,0.0002861627,0.0002339486,0.0001705755,0.001163039,0.0000158799],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9737137,0.01549205,0.0006134739,0.001985274,0.001227991,0.001974666,0.001379686,0.0001671089,0.00344611],"genre_scores_gemma":[0.9847467,0.005336866,0.000717897,0.001394748,0.0004992188,0.001518854,0.0009323997,0.00002540453,0.004827898],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006385579,"threshold_uncertainty_score":0.02136183,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2132165198","doi":"10.1038/nm.1790","title":"Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study","year":2008,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1243,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Queen's University; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; U.S. Public Health Service","keywords":"Lung cancer; Adenocarcinoma; Oncology; Stage (stratigraphy); Internal medicine; Covariate; Microarray analysis techniques; Survival analysis; Microarray; Medicine; Cancer; Bioinformatics; Gene expression; Gene; Biology; Computer science; Machine learning; Genetics","authors":[{"name":"Kerby Shedden","is_ca":false},{"name":"David G. Beer","is_ca":false},{"name":"Rork Kuick","is_ca":true},{"name":"Samir Hanash","is_ca":false},{"name":"Andrew C. Chang","is_ca":false},{"name":"Jeremy M. G. Taylor","is_ca":false},{"name":"David E. Misek","is_ca":true},{"name":"Steven A. Eschrich","is_ca":false},{"name":"Michael E. Gruidl","is_ca":false},{"name":"Steven A. Enkemann","is_ca":true},{"name":"Anupama Sharma","is_ca":true},{"name":"Timothy J. Yeatman","is_ca":true},{"name":"Chang‐Qi Zhu","is_ca":true},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Daniel Strumpf","is_ca":true},{"name":"Igor Jurišica","is_ca":false},{"name":"János Szőke","is_ca":false},{"name":"Noriko Motoi","is_ca":false},{"name":"Mark G. Kris","is_ca":false},{"name":"Valerie W. Rusch","is_ca":false},{"name":"Agnès Viale","is_ca":false},{"name":"William L. Gerald","is_ca":false},{"name":"Maureen F. Zakowski","is_ca":false},{"name":"William D. Travis","is_ca":true},{"name":"Thomas J. Giordano","is_ca":true},{"name":"Keyue Ding","is_ca":false},{"name":"Lesley Seymour","is_ca":false},{"name":"Nathan A. Pennell","is_ca":false},{"name":"Matthew Meyerson","is_ca":false},{"name":"Katsuhiko Naoki","is_ca":false},{"name":"Barbara A. Weir","is_ca":false},{"name":"Christine Ladd‐Acosta","is_ca":false},{"name":"Todd R. Golub","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.036264107200383,"gpt":0.3620844392133409,"spread":0.325820332012958,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01425684,0.001363495,0.001598546,0.0004936958,0.001088116,0.001213707,0.001130263,0.001942129,0.0009407816],"category_scores_gemma":[0.01290109,0.0008054863,0.001480675,0.0005003769,0.001860351,0.0008740737,0.0008486321,0.001481559,0.0005980862],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008229621,"about_ca_system_score_gemma":0.0009009732,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001938575,"about_ca_topic_score_gemma":0.002620213,"domain_scores_codex":[0.9931297,0.004028087,0.0002986693,0.00146904,0.0007710531,0.000303394],"domain_scores_gemma":[0.9830474,0.00783841,0.001887315,0.004556369,0.001913393,0.0007571715],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1370028,0.006005297,0.7536509,0.0002970839,0.005650179,0.0005820344,0.001155321,0.005999547,0.05027172,0.0002263819,0.001563334,0.03759542],"study_design_scores_gemma":[0.01408856,0.02650074,0.9187391,0.00005259988,0.003901093,0.001668524,0.0003127751,0.0144676,0.01698344,0.0005604114,0.002499426,0.0002257119],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968953,0.000264968,0.001970853,0.00004001383,0.00003115333,0.0001258559,0.0004208372,0.00001652431,0.0002346139],"genre_scores_gemma":[0.9967969,0.00008109141,0.001275765,0.00008566544,0.00003909704,0.0001195284,0.001277369,0.00001887388,0.0003056997],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01425684,"threshold_uncertainty_score":0.07539833,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2339311613","doi":"10.1016/s1470-2045(16)30033-x","title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1175,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"European Society for Medical Oncology; Boehringer Ingelheim","keywords":"Afatinib; Gefitinib; Medicine; Internal medicine; Lung cancer; Oncology; Population; Clinical endpoint; Randomized controlled trial; Epidermal growth factor receptor; Cancer","authors":[{"name":"Keunchil Park","is_ca":false},{"name":"Eng-Huat Tan","is_ca":false},{"name":"Kenneth J. O’Byrne","is_ca":false},{"name":"Li Zhang","is_ca":false},{"name":"Michael Boyer","is_ca":false},{"name":"Tony Mok","is_ca":false},{"name":"Vera Hirsh","is_ca":true},{"name":"James Chih‐Hsin Yang","is_ca":false},{"name":"Ki Hyeong Lee","is_ca":false},{"name":"Shun Lü","is_ca":false},{"name":"Yuankai Shi","is_ca":false},{"name":"Sang-We Kim","is_ca":false},{"name":"Janessa Laskin","is_ca":true},{"name":"Dong‐Wan Kim","is_ca":false},{"name":"Catherine Dubos Arvis","is_ca":false},{"name":"Karl Kölbeck","is_ca":false},{"name":"Scott A. Laurie","is_ca":true},{"name":"Chun-Ming Tsai","is_ca":false},{"name":"Mehdi Shahidi","is_ca":false},{"name":"Miyoung Kim","is_ca":false},{"name":"Dan Massey","is_ca":false},{"name":"Victoria Zazulina","is_ca":false},{"name":"Luis Paz‐Ares","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04042620639566981,"gpt":0.4065506950648967,"spread":0.3661244886692269,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002021232,0.002557346,0.005699834,0.0005523631,0.0004880276,0.001678903,0.001400876,0.003170215,0.007954195],"category_scores_gemma":[0.002475582,0.0009701212,0.004581523,0.0004957592,0.001649494,0.002214848,0.0005165339,0.004764134,0.001521911],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001114053,"about_ca_system_score_gemma":0.001117883,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001262787,"about_ca_topic_score_gemma":0.002909564,"domain_scores_codex":[0.9989942,0.0005000847,0.00006712015,0.000202333,0.00006572564,0.0001705098],"domain_scores_gemma":[0.9990222,0.0003273113,0.0001981005,0.00007016165,0.00007132019,0.0003109092],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9862153,0.001657608,0.0002581927,0.0008598177,0.00129472,0.00003139125,0.000035167,0.0002842268,0.000832273,0.00008889875,0.0007185132,0.007723949],"study_design_scores_gemma":[0.976469,0.02175563,0.0004557736,0.00002785865,0.0004760611,0.00002749625,0.00001652364,0.0002559519,0.00009660816,0.000110761,0.0002953969,0.00001291374],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9680918,0.01771316,0.001035291,0.001978092,0.002107888,0.003588949,0.001848806,0.0003064121,0.00332953],"genre_scores_gemma":[0.9838048,0.005275236,0.001317965,0.00141851,0.0007005581,0.002538042,0.001333908,0.0000378046,0.003573262],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007954195,"threshold_uncertainty_score":0.02660948,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3101089668","doi":"10.1056/nejmoa2027187","title":"First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1064,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Research UK; Pfizer","keywords":"Crizotinib; Anaplastic lymphoma kinase; ALK inhibitor; Lung cancer; Cancer research; Medicine; Internal medicine; Oncology","authors":[{"name":"Alice T. Shaw","is_ca":false},{"name":"Todd M. Bauer","is_ca":false},{"name":"Filippo de Marinis","is_ca":false},{"name":"Enriqueta Felip","is_ca":false},{"name":"Yasushi Goto","is_ca":false},{"name":"Geoffrey Liu","is_ca":true},{"name":"Julien Mazières","is_ca":false},{"name":"Dong‐Wan Kim","is_ca":false},{"name":"Tony Mok","is_ca":false},{"name":"Anna Polli","is_ca":false},{"name":"Holger Thurm","is_ca":false},{"name":"Anna Maria Calella","is_ca":false},{"name":"Gerson Peltz","is_ca":false},{"name":"Benjamin Solomon","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02574200789427179,"gpt":0.3619308581690756,"spread":0.3361888502748038,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001018804,0.0002646435,0.0007940938,0.0001867526,0.0001305916,0.0003765257,0.0003536005,0.0002784928,0.001038264],"category_scores_gemma":[0.00173529,0.00008018268,0.0004772625,0.0002222016,0.000149848,0.0002039362,0.0001390607,0.0005628273,0.0001888578],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009637053,"about_ca_system_score_gemma":0.0007027813,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008659295,"about_ca_topic_score_gemma":0.003178408,"domain_scores_codex":[0.9996531,0.0001773473,0.00003230132,0.0000356338,0.00005494619,0.00004664129],"domain_scores_gemma":[0.9993792,0.0001653637,0.0002281331,0.00002348908,0.00005658658,0.0001471715],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1282235,0.002258768,0.1880452,0.005181463,0.003470806,0.001157344,0.0001985201,0.003632524,0.01690597,0.0002608654,0.01400459,0.6366603],"study_design_scores_gemma":[0.05610426,0.10709,0.7509196,0.00146641,0.006887888,0.01163562,0.0002992293,0.008700921,0.02083331,0.0007142682,0.03526773,0.00008083002],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.935586,0.05881425,0.0003457065,0.001167176,0.0001148101,0.0001735841,0.000398617,0.00005663834,0.003343294],"genre_scores_gemma":[0.9917966,0.006895158,0.0002211108,0.0002792512,0.000095442,0.00004843329,0.0003197884,0.000004102328,0.0003401167],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001038264,"threshold_uncertainty_score":0.006992161,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2154969724","doi":"10.1146/annurev-pathol-011110-130206","title":"EGFR Mutations and Lung Cancer","year":2011,"lang":"en","type":"review","venue":"Annual Review of Pathology Mechanisms of Disease","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":970,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Epidermal growth factor receptor; Tyrosine kinase; Protein kinase domain; Cancer research; Lung cancer; Mutation; Medicine; Receptor tyrosine kinase; Kinase; Targeted therapy; Mutant; EGFR inhibitors; Cancer; Biology; Oncology; Internal medicine; Gene; Receptor; Cell biology; Genetics","authors":[{"name":"Gilda da Cunha Santos","is_ca":true},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Ming‐Sound Tsao","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02528738243119175,"gpt":0.4057506192605896,"spread":0.3804632368293979,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002943551,0.0005354706,0.0007800886,0.001447609,0.0002162948,0.000670056,0.0005832923,0.0008019052,0.003937541],"category_scores_gemma":[0.0005119089,0.0001677157,0.0003090562,0.001687382,0.0002824668,0.0008186525,0.0004907818,0.00102426,0.003601518],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005419956,"about_ca_system_score_gemma":0.0008886416,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001174258,"about_ca_topic_score_gemma":0.001983875,"domain_scores_codex":[0.999826,0.00003044415,0.00002137508,0.00002788495,0.00007851038,0.00001585138],"domain_scores_gemma":[0.9998744,0.00003813434,0.00002571599,0.000004104354,0.0000428643,0.00001472563],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004506587,0.00004183554,0.0003688822,0.01198765,0.00006148329,0.000420142,0.00006234054,0.0001551775,0.001728646,0.002248683,0.0531872,0.929693],"study_design_scores_gemma":[0.00001030095,0.00004424312,0.0012941,0.002710568,0.00005604131,0.003520489,0.00004568522,0.00002732921,0.0003434481,0.001272635,0.9906652,0.0000100039],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00009760173,0.9983287,0.00003568167,0.0002076198,0.0001391998,0.000002172013,0.00001088566,0.000003874234,0.00117424],"genre_scores_gemma":[0.000907493,0.9976867,0.00007531357,0.000224374,0.0001555259,0.000003631859,0.00002619983,0.000001001749,0.0009196297],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003937541,"threshold_uncertainty_score":0.01317239,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2152905269","doi":"10.1016/s1470-2045(12)70087-6","title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":953,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Afatinib; Medicine; Erlotinib; Gefitinib; Internal medicine; Clinical endpoint; Hazard ratio; Placebo; Lung cancer; Oncology; Performance status; Chemotherapy; Adenocarcinoma; Randomized controlled trial; Surgery; Cancer; Epidermal growth factor receptor; Confidence interval; Pathology","authors":[{"name":"Vincent A. Miller","is_ca":false},{"name":"Vera Hirsh","is_ca":true},{"name":"Jacques Cadranel","is_ca":false},{"name":"Yuh-Min Chen","is_ca":false},{"name":"Keunchil Park","is_ca":false},{"name":"Sang-We Kim","is_ca":false},{"name":"Caicun Zhou","is_ca":false},{"name":"Wu‐Chou Su","is_ca":false},{"name":"Mengzhao Wang","is_ca":false},{"name":"Yan Sun","is_ca":false},{"name":"Dae Seog Heo","is_ca":false},{"name":"Lucio Crinò","is_ca":false},{"name":"Eng-Huat Tan","is_ca":false},{"name":"Tsu-Yi Chao","is_ca":false},{"name":"Mehdi Shahidi","is_ca":false},{"name":"Xiuyu Julie Cong","is_ca":false},{"name":"Robert M. Lorence","is_ca":false},{"name":"James Chih‐Hsin Yang","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03765453655497886,"gpt":0.403575366148624,"spread":0.3659208295936452,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001970906,0.002389709,0.005274345,0.0005748309,0.0005625978,0.001466907,0.001067507,0.003178598,0.008294312],"category_scores_gemma":[0.002467905,0.0008116649,0.004036337,0.0005327513,0.001764522,0.00217747,0.0005861023,0.004395033,0.001597802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008511507,"about_ca_system_score_gemma":0.0008813021,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009586675,"about_ca_topic_score_gemma":0.001782435,"domain_scores_codex":[0.9990678,0.000450717,0.00007865146,0.0001942424,0.000044376,0.0001641996],"domain_scores_gemma":[0.9990797,0.000308523,0.0001829571,0.00007266788,0.00005260613,0.0003034547],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9891192,0.001189731,0.0002088018,0.0005034719,0.0008368677,0.00003129557,0.00003335799,0.0002082355,0.0008754985,0.00008423895,0.000461633,0.006447704],"study_design_scores_gemma":[0.9740978,0.02423607,0.0004443209,0.00002277399,0.0003513021,0.00002696649,0.00001835227,0.0001926261,0.0001178844,0.0001945024,0.0002853753,0.00001211033],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9738818,0.01284208,0.000881224,0.002446824,0.002175529,0.002925971,0.001443496,0.0002542336,0.00314881],"genre_scores_gemma":[0.9884259,0.003068747,0.0007828276,0.001243061,0.0006336986,0.001741018,0.0006707364,0.00002475732,0.003409344],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008294312,"threshold_uncertainty_score":0.02774727,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2125665528","doi":"10.1200/jco.2015.62.1342","title":"Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":851,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Medicine; Pemetrexed; Oncology; Gefitinib; Erlotinib; Internal medicine; Crizotinib; Docetaxel; Lung cancer; Carboplatin; Afatinib; Chemotherapy; Bevacizumab; Cancer; Epidermal growth factor receptor; Malignant pleural effusion; Cisplatin","authors":[{"name":"Gregory A. Masters","is_ca":false},{"name":"Sarah Temin","is_ca":false},{"name":"Christopher G. Azzoli","is_ca":false},{"name":"Giuseppe Giaccone","is_ca":false},{"name":"Sherman Baker","is_ca":false},{"name":"Julie R. Brahmer","is_ca":false},{"name":"Ajeet Gajra","is_ca":false},{"name":"Nancy Rackear","is_ca":false},{"name":"Joan H. Schiller","is_ca":false},{"name":"Thomas J. Smith","is_ca":false},{"name":"John R. Strawn","is_ca":false},{"name":"David Trent","is_ca":false},{"name":"David H. Johnson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.197713970446764,"gpt":0.6016853804165807,"spread":0.4039714099698167,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007163749,0.001204111,0.002467314,0.00410662,0.0008858463,0.00214594,0.003677698,0.004062608,0.0070502],"category_scores_gemma":[0.02307389,0.0006518963,0.00384883,0.005361419,0.0007012115,0.002280446,0.001827965,0.005433438,0.005192528],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004304858,"about_ca_system_score_gemma":0.01554605,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02128155,"about_ca_topic_score_gemma":0.04602343,"domain_scores_codex":[0.9927819,0.0023332,0.001921668,0.0003488676,0.002317649,0.0002968232],"domain_scores_gemma":[0.9813488,0.00372519,0.00275096,0.0003501712,0.01094936,0.0008754997],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005241246,0.0001054839,0.00102085,0.01195532,0.0002759293,0.0001517416,0.0001788375,0.0006583161,0.0002570355,0.002067242,0.6990719,0.284205],"study_design_scores_gemma":[0.0002747593,0.00008418178,0.003083523,0.04767641,0.0008462252,0.0006271396,0.0001535441,0.0005869434,0.0001982178,0.003578243,0.9428328,0.00005806641],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"editorial","genre_scores_codex":[0.003172264,0.6189299,0.01688035,0.2342659,0.01373299,0.006907585,0.01847011,0.001002372,0.08663854],"genre_scores_gemma":[0.01372425,0.7605954,0.08093909,0.07551815,0.006024716,0.00821307,0.03728178,0.0003329264,0.01737052],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.02128155,"threshold_uncertainty_score":0.04231536,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2154662831","doi":"10.1200/jco.2011.36.8456","title":"First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":735,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CAE (Canada)","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Cisplatin; Internal medicine; Adenocarcinoma; Lung cancer; Chemotherapy; Lung; Cancer","authors":[{"name":"Ji‐Youn Han","is_ca":true},{"name":"Keunchil Park","is_ca":true},{"name":"Sang‐We Kim","is_ca":true},{"name":"Ki Hyeong Lee","is_ca":true},{"name":"Hyae Young Kim","is_ca":true},{"name":"Heung Tae Kim","is_ca":true},{"name":"Myung‐Ju Ahn","is_ca":true},{"name":"Tak Yun","is_ca":true},{"name":"Jin Seok Ahn","is_ca":true},{"name":"Cheolwon Suh","is_ca":true},{"name":"Jung‐Shin Lee","is_ca":true},{"name":"Sung Jin Yoon","is_ca":true},{"name":"Jong Hee Han","is_ca":true},{"name":"Jae‐Won Lee","is_ca":true},{"name":"Sook Jung Jo","is_ca":true},{"name":"Jin Soo Lee","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.131847856307436,"gpt":0.4544081414491074,"spread":0.3225602851416715,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001350249,0.001124954,0.002737541,0.0003070324,0.0002941736,0.0008936581,0.0008992194,0.001403825,0.004271726],"category_scores_gemma":[0.001000006,0.0004272016,0.001507753,0.0002799722,0.0007998507,0.0008651257,0.0004043519,0.002420738,0.0007367437],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009074935,"about_ca_system_score_gemma":0.001069948,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00062619,"about_ca_topic_score_gemma":0.002136718,"domain_scores_codex":[0.9996044,0.0002020521,0.00002848866,0.00007515232,0.00003631177,0.00005357348],"domain_scores_gemma":[0.9992913,0.0001315133,0.0001754721,0.00003978751,0.00003352534,0.0003284508],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9506655,0.007570285,0.002958522,0.0007929275,0.001355982,0.00006663489,0.00007945659,0.0008363075,0.005453675,0.00007575253,0.001038636,0.02910624],"study_design_scores_gemma":[0.8268318,0.1600344,0.008336067,0.00004667631,0.0008754634,0.0001763008,0.00003622261,0.001140555,0.001522833,0.0001067987,0.0008737693,0.00001910886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956242,0.002153398,0.000157497,0.0002786147,0.0001105514,0.0006820626,0.0003333557,0.00004919286,0.0006111659],"genre_scores_gemma":[0.9939618,0.001400336,0.0005582382,0.0005644262,0.0001796722,0.001144806,0.0009292007,0.00001393162,0.001247679],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004271726,"threshold_uncertainty_score":0.01429033,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2139939379","doi":"10.1634/theoncologist.2008-0232","title":"The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies","year":2009,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":692,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Docetaxel; Gemcitabine; Oncology; Internal medicine; Histology; Hazard ratio; Lung cancer; Proportional hazards model; Chemotherapy; Cisplatin; Confidence interval","authors":[{"name":"Giorgio V. Scagliotti","is_ca":false},{"name":"Nasser H. Hanna","is_ca":false},{"name":"Frank V. Fossella","is_ca":false},{"name":"Katherine P. Sugarman","is_ca":false},{"name":"J. Blatter","is_ca":false},{"name":"Patrick Peterson","is_ca":false},{"name":"Lorinda Simms","is_ca":true},{"name":"Frances A. Shepherd","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1300508911499699,"gpt":0.5312090846097777,"spread":0.4011581934598078,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01630493,0.0008188924,0.005053881,0.002444502,0.0003372575,0.002310836,0.001842521,0.001097849,0.001382204],"category_scores_gemma":[0.02462952,0.0005813939,0.004456837,0.004298375,0.0007909087,0.001347863,0.0007908315,0.001600138,0.0002205016],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001798408,"about_ca_system_score_gemma":0.002929235,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001041945,"about_ca_topic_score_gemma":0.002861916,"domain_scores_codex":[0.9956788,0.001371339,0.00176735,0.0004061596,0.0006686414,0.0001077159],"domain_scores_gemma":[0.9685767,0.01967671,0.007475128,0.0007189846,0.003069422,0.0004830599],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.006292912,0.0002533458,0.00363922,0.2782051,0.01188558,0.0001882523,0.0003951087,0.0004132254,0.003741581,0.0007897239,0.006536813,0.687659],"study_design_scores_gemma":[0.007416517,0.01562073,0.04415611,0.4086481,0.1697425,0.002718678,0.0008606572,0.000705537,0.00763487,0.00210517,0.3401494,0.0002417469],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001979381,0.9966633,0.0002413164,0.0003593941,0.0001125765,0.0001282443,0.0001319482,0.00001049606,0.0003734266],"genre_scores_gemma":[0.0247067,0.9714819,0.001086067,0.00163991,0.000194747,0.0003479202,0.0003285239,0.00002650898,0.0001878416],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01630493,"threshold_uncertainty_score":0.08622974,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2105026490","doi":"10.1200/jco.2007.14.8924","title":"Role of <i>KRAS</i> and <i>EGFR</i> As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":665,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Erlotinib; KRAS; Medicine; Epidermal growth factor receptor; Hazard ratio; Fluorescence in situ hybridization; EGFR inhibitors; Internal medicine; Oncology; Erlotinib Hydrochloride; Cancer research; Cancer; Biology; Gene; Colorectal cancer; Genetics; Confidence interval","authors":[{"name":"Chang‐Qi Zhu","is_ca":true},{"name":"Gilda da Cunha Santos","is_ca":true},{"name":"Keyue Ding","is_ca":true},{"name":"Akira Sakurada","is_ca":true},{"name":"Jean-Claude Cutz","is_ca":true},{"name":"Geoffrey Liu","is_ca":true},{"name":"Tong Zhang","is_ca":true},{"name":"Paula Marrano","is_ca":true},{"name":"Marlo Whitehead","is_ca":true},{"name":"Jeremy A. Squire","is_ca":true},{"name":"Suzanne Kamel‐Reid","is_ca":true},{"name":"Lesley Seymour","is_ca":true},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Ming‐Sound Tsao","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1692448192514435,"gpt":0.5560504929225468,"spread":0.3868056736711033,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01126488,0.001165673,0.002877533,0.0005048424,0.0004240123,0.001444116,0.0009821291,0.001302485,0.001499469],"category_scores_gemma":[0.01023589,0.0004610076,0.001625836,0.0006750019,0.0008299541,0.000684068,0.0003487437,0.00166384,0.0002497151],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001690491,"about_ca_system_score_gemma":0.002224728,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00553385,"about_ca_topic_score_gemma":0.01779223,"domain_scores_codex":[0.9934108,0.004954733,0.0002902422,0.0004672758,0.0005901512,0.000286884],"domain_scores_gemma":[0.9888681,0.00407324,0.004328573,0.0006476094,0.0008996158,0.001182983],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7869942,0.001184631,0.1616691,0.001041092,0.00574119,0.00007763504,0.0001131107,0.001268893,0.003902092,0.0001725677,0.0018172,0.03601817],"study_design_scores_gemma":[0.2079644,0.05621645,0.7136186,0.0003902522,0.0101719,0.0003530853,0.00008852213,0.004568655,0.001890391,0.0004175646,0.004159176,0.0001609952],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9699633,0.02339418,0.0004280882,0.0007878997,0.0001161657,0.0007277954,0.001784986,0.00004632616,0.002751273],"genre_scores_gemma":[0.9947149,0.001304972,0.0006282188,0.0005155032,0.0001438958,0.0005109531,0.001515596,0.00001890279,0.0006470964],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9944661,"threshold_uncertainty_score":0.05957508,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4242460399","doi":"10.1200/jco.2017.74.6065","title":"Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":650,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Association for Molecular Pathology; American Society of Clinical Oncology; American Association for Cancer Research","keywords":"Medicine; Atezolizumab; Nivolumab; Pembrolizumab; Oncology; Internal medicine; Lung cancer; Guideline; Docetaxel; Pemetrexed; Chemotherapy; Clinical trial; Cancer; Intensive care medicine; Immunotherapy; Pathology; Cisplatin","authors":[{"name":"Nasser H. Hanna","is_ca":false},{"name":"David H. Johnson","is_ca":false},{"name":"Sarah Temin","is_ca":false},{"name":"Sherman Baker","is_ca":false},{"name":"Julie R. Brahmer","is_ca":false},{"name":"Giuseppe Giaccone","is_ca":false},{"name":"Paul J. Hesketh","is_ca":false},{"name":"Ishmael Jaiyesimi","is_ca":false},{"name":"Natasha B. Leighl","is_ca":false},{"name":"Gregory J. Riely","is_ca":false},{"name":"Joan H. Schiller","is_ca":false},{"name":"Bryan J. Schneider","is_ca":false},{"name":"Thomas J. Smith","is_ca":false},{"name":"Joan Tashbar","is_ca":false},{"name":"William A. Biermann","is_ca":false},{"name":"Gregory A. Masters","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1717391177742632,"gpt":0.6087778275094344,"spread":0.4370387097351712,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009930776,0.001313998,0.002677516,0.004833305,0.001070477,0.002831473,0.003802397,0.004970651,0.007580738],"category_scores_gemma":[0.03881859,0.0007718513,0.004971622,0.005701507,0.0007839918,0.002952634,0.002253084,0.005925884,0.005673259],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004477402,"about_ca_system_score_gemma":0.01748816,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01878451,"about_ca_topic_score_gemma":0.04192238,"domain_scores_codex":[0.9897132,0.003230978,0.00326926,0.0004721726,0.002945485,0.0003689056],"domain_scores_gemma":[0.9677725,0.007257355,0.004785026,0.0006382724,0.01832707,0.001219811],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005864748,0.0001082586,0.0009719022,0.01854705,0.0003562552,0.000171712,0.0002496387,0.0006607731,0.0002849818,0.00245282,0.6741895,0.3019485],"study_design_scores_gemma":[0.0003037614,0.00008828654,0.002600786,0.07748397,0.00101927,0.0005920586,0.0001838627,0.0006344893,0.0002276938,0.005639348,0.911147,0.00007933828],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"other","genre_scores_codex":[0.002931103,0.582189,0.02023881,0.2803135,0.01944305,0.00799136,0.016774,0.000964577,0.06915472],"genre_scores_gemma":[0.01306973,0.6912302,0.1267491,0.1048733,0.007396676,0.01084642,0.02772488,0.0003881252,0.01772156],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.01878451,"threshold_uncertainty_score":0.05251956,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2115330744","doi":"10.1093/annonc/mdq020","title":"Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":644,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bevacizumab; Medicine; Gemcitabine; Hazard ratio; Clinical endpoint; Internal medicine; Placebo; Lung cancer; Oncology; Cisplatin; Progression-free survival; Chemotherapy; Confidence interval; Surgery; Urology; Gastroenterology; Clinical trial; Pathology","authors":[{"name":"Martin Reck","is_ca":false},{"name":"Joachim von Pawel","is_ca":false},{"name":"Petr Zatloukal","is_ca":false},{"name":"Rodryg Ramlau","is_ca":false},{"name":"V. Gorbounova","is_ca":false},{"name":"Vera Hirsh","is_ca":false},{"name":"N. B. Leighl","is_ca":true},{"name":"J. Mezger","is_ca":false},{"name":"Venice Archer","is_ca":false},{"name":"Norman C. Moore","is_ca":false},{"name":"C. Manegold","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0480325960961244,"gpt":0.4125897085681237,"spread":0.3645571124719993,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002638464,0.001978523,0.005350374,0.0007588262,0.0006138067,0.001528856,0.001282113,0.002769051,0.01017266],"category_scores_gemma":[0.002467722,0.001073456,0.003725007,0.0008721412,0.001954716,0.002327906,0.0008593132,0.005821549,0.001656948],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001536777,"about_ca_system_score_gemma":0.001502273,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001876871,"about_ca_topic_score_gemma":0.004233189,"domain_scores_codex":[0.9988831,0.0006313598,0.00006584418,0.0002106111,0.00005588671,0.0001532524],"domain_scores_gemma":[0.9985715,0.0004465957,0.0002585438,0.0001219894,0.00006112778,0.0005401197],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9865664,0.001964233,0.0002394711,0.0003600601,0.0006443725,0.00001407286,0.00003388683,0.000313925,0.0009924864,0.00004135336,0.0004083046,0.008421432],"study_design_scores_gemma":[0.9639728,0.03400359,0.0008160865,0.00002460153,0.000477714,0.00001708195,0.00001385031,0.000141906,0.000176399,0.00007429195,0.0002721683,0.000009491139],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9793984,0.008906656,0.0008030517,0.001704417,0.001076113,0.003339052,0.001992942,0.0001943899,0.002584867],"genre_scores_gemma":[0.9806958,0.004810794,0.0017642,0.001382775,0.0006709941,0.004138148,0.002090857,0.00007519541,0.004371244],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01017266,"threshold_uncertainty_score":0.03403097,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2536396512","doi":"10.1016/s1470-2045(16)30508-3","title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":643,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University of Ottawa; Ottawa Hospital","funders":"National Cancer Institute; AstraZeneca","keywords":"Osimertinib; Lung cancer; Medicine; Open label; Cancer; Oncology; Internal medicine; Adenocarcinoma; Clinical trial","authors":[{"name":"Glenwood Goss","is_ca":true},{"name":"Chun‐Ming Tsai","is_ca":false},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Lyudmila Bazhenova","is_ca":false},{"name":"Jong Seok Lee","is_ca":false},{"name":"Gee‐Chen Chang","is_ca":false},{"name":"Lucio Crinò","is_ca":false},{"name":"Miyako Satouchi","is_ca":false},{"name":"Quincy S. Chu","is_ca":true},{"name":"Toyoaki Hida","is_ca":false},{"name":"Ji‐Youn Han","is_ca":false},{"name":"Óscar Juan","is_ca":false},{"name":"Frank Dunphy","is_ca":false},{"name":"Makoto Nishio","is_ca":false},{"name":"Jin‐Hyoung Kang","is_ca":false},{"name":"Margarita Majem","is_ca":false},{"name":"Helen Mann","is_ca":false},{"name":"Mireille Cantarini","is_ca":false},{"name":"Serban Ghiorghiu","is_ca":false},{"name":"Tetsuya Mitsudomi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06472232217388303,"gpt":0.4461270129553907,"spread":0.3814046907815077,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001634801,0.002609258,0.002632469,0.0003979639,0.0004427932,0.001466171,0.000785864,0.00152619,0.003819875],"category_scores_gemma":[0.0007192465,0.0007965519,0.002139258,0.0004988929,0.001114857,0.001598369,0.0003868459,0.003209376,0.001123538],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001092339,"about_ca_system_score_gemma":0.001181345,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001282975,"about_ca_topic_score_gemma":0.004790141,"domain_scores_codex":[0.9995853,0.0001534898,0.00001699324,0.00008059953,0.00004155089,0.0001219128],"domain_scores_gemma":[0.999603,0.00005671899,0.0000751707,0.00004182718,0.00002759143,0.0001956562],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8969789,0.02054895,0.003584526,0.0008601741,0.002161158,0.0001708666,0.0001908736,0.001831334,0.01752984,0.0002469678,0.003393343,0.05250306],"study_design_scores_gemma":[0.8189529,0.1677262,0.008059401,0.00002950567,0.0007482519,0.0001803492,0.00007494826,0.0009234325,0.001126028,0.0002561426,0.001880932,0.00004199925],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926468,0.002059298,0.0004438233,0.0003657614,0.0001955537,0.001365529,0.001201809,0.00009996919,0.001621411],"genre_scores_gemma":[0.9861974,0.002607797,0.001160447,0.0009731709,0.0002235665,0.001706324,0.002605241,0.0000539532,0.00447196],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003819875,"threshold_uncertainty_score":0.01277876,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2784623697","doi":"10.1016/j.jtho.2017.12.001","title":"Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":633,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Guideline; Medicine; KRAS; ROS1; Lung cancer; Context (archaeology); Targeted therapy; Companion diagnostic; Pathology; Oncology; Internal medicine; Medical physics; Adenocarcinoma; Cancer; Family medicine; Intensive care medicine","authors":[{"name":"Neal I. Lindeman","is_ca":false},{"name":"Philip T. Cagle","is_ca":false},{"name":"Dara L. Aisner","is_ca":false},{"name":"Maria E. Arcila","is_ca":false},{"name":"Mary Beth Beasley","is_ca":false},{"name":"Eric Bernicker","is_ca":false},{"name":"Carol Colasacco","is_ca":false},{"name":"Sanja Đačić","is_ca":false},{"name":"Fred R. Hirsch","is_ca":false},{"name":"Keith M. Kerr","is_ca":false},{"name":"David J. Kwiatkowski","is_ca":false},{"name":"Marc Ladanyi","is_ca":false},{"name":"Jan A. Nowak","is_ca":false},{"name":"Lynette M. Sholl","is_ca":false},{"name":"Robyn Temple‐Smolkin","is_ca":false},{"name":"Benjamin Solomon","is_ca":false},{"name":"Lesley Souter","is_ca":false},{"name":"Erik Thunnissen","is_ca":false},{"name":"Ming‐Sound Tsao","is_ca":true},{"name":"Christina B. Ventura","is_ca":false},{"name":"Murry W. Wynes","is_ca":false},{"name":"Yasushi Yatabe","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01968033351421288,"gpt":0.4325975365504492,"spread":0.4129172030362364,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005030996,0.001088196,0.002064527,0.002355075,0.0008489568,0.002120206,0.003289058,0.005169418,0.003842588],"category_scores_gemma":[0.01322638,0.0006291341,0.003832917,0.00191905,0.0006593124,0.001201016,0.001463125,0.007104483,0.002946292],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003023572,"about_ca_system_score_gemma":0.005700361,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02186394,"about_ca_topic_score_gemma":0.03945196,"domain_scores_codex":[0.9954614,0.001207067,0.001525383,0.0002730582,0.001214319,0.0003187962],"domain_scores_gemma":[0.9864947,0.004086561,0.001331698,0.0002926404,0.006908391,0.0008861304],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002413266,0.0002863945,0.0129987,0.0009686874,0.0002779956,0.001252934,0.0001990353,0.00312272,0.002890468,0.004439707,0.793875,0.179447],"study_design_scores_gemma":[0.0006198529,0.0004543384,0.06755283,0.009401407,0.001210044,0.006801108,0.0003707659,0.005898677,0.003713503,0.01208619,0.8917167,0.0001745836],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.02791448,0.1331964,0.08338241,0.5321371,0.01975234,0.003963617,0.04369527,0.00390056,0.1520579],"genre_scores_gemma":[0.1530319,0.1098478,0.2324588,0.3304216,0.01622169,0.007083657,0.09449765,0.001232456,0.05520454],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.02186394,"threshold_uncertainty_score":0.04347336,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3191219220","doi":"10.1200/jco.21.00662","title":"Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":632,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Cedars-Sinai Medical Center","keywords":"Medicine; Rash; Lung cancer; Internal medicine; Population; Adverse effect; Epidermal growth factor receptor; Erlotinib; Oncology; Gastroenterology; Cancer","authors":[{"name":"Keunchil Park","is_ca":false},{"name":"Eric B. Haura","is_ca":false},{"name":"Natasha B. Leighl","is_ca":true},{"name":"Paul Mitchell","is_ca":false},{"name":"Catherine A. Shu","is_ca":false},{"name":"Nicolas Girard","is_ca":false},{"name":"Santiago Viteri","is_ca":false},{"name":"Ji‐Youn Han","is_ca":false},{"name":"Sang‐We Kim","is_ca":false},{"name":"Chee Khoon Lee","is_ca":false},{"name":"Joshua K. Sabari","is_ca":false},{"name":"Alexander I. Spira","is_ca":false},{"name":"Tsung‐Ying Yang","is_ca":false},{"name":"Dong‐Wan Kim","is_ca":false},{"name":"Ki Hyeong Lee","is_ca":false},{"name":"Rachel E. Sanborn","is_ca":false},{"name":"José Trigo","is_ca":false},{"name":"Kōichi Goto","is_ca":false},{"name":"Jong‐Seok Lee","is_ca":false},{"name":"James Chih‐Hsin Yang","is_ca":false},{"name":"Ramaswamy Govindan","is_ca":false},{"name":"Joshua Bauml","is_ca":false},{"name":"Pilar Garrido","is_ca":false},{"name":"Matthew Krebs","is_ca":false},{"name":"Karen L. Reckamp","is_ca":false},{"name":"John Xie","is_ca":false},{"name":"Joshua C. Curtin","is_ca":false},{"name":"Nahor Haddish‐Berhane","is_ca":false},{"name":"Amy Roshak","is_ca":false},{"name":"Dawn Millington","is_ca":false},{"name":"Patricia Lorenzini","is_ca":false},{"name":"Meena Thayu","is_ca":false},{"name":"Roland E. Knoblauch","is_ca":false},{"name":"Byoung Chul Cho","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1015364525497676,"gpt":0.5266134971143889,"spread":0.4250770445646213,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001093185,0.0007472862,0.0009632834,0.000295154,0.0002619028,0.0006095716,0.000385071,0.0005220934,0.0009968588],"category_scores_gemma":[0.000546868,0.000198622,0.0006704457,0.0002845763,0.0004326729,0.0004294438,0.0002302477,0.001319607,0.0002733868],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007642603,"about_ca_system_score_gemma":0.0007084376,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001241453,"about_ca_topic_score_gemma":0.003530309,"domain_scores_codex":[0.9996911,0.0001344975,0.00001901495,0.00004002485,0.00005230086,0.00006295263],"domain_scores_gemma":[0.9996106,0.000082342,0.0000623853,0.00003094204,0.00003617691,0.0001774142],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2287443,0.05538278,0.03697156,0.001533009,0.002138589,0.001051158,0.0009793118,0.006353311,0.336647,0.0005045451,0.005465469,0.3242289],"study_design_scores_gemma":[0.1409514,0.6924888,0.1097673,0.00009499725,0.001499408,0.001688698,0.0002418386,0.003480696,0.04213567,0.0003555119,0.007233879,0.00006173753],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956774,0.002081613,0.0002272389,0.0001720837,0.00002161617,0.0003692168,0.0003092746,0.00003068509,0.001110901],"genre_scores_gemma":[0.9959462,0.001732841,0.0003745714,0.0001911087,0.00003855235,0.0001863965,0.0008037866,0.00001302329,0.0007133791],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001241453,"threshold_uncertainty_score":0.005781353,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4379280261","doi":"10.1056/nejmoa2304594","title":"Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":612,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Medicine; Osimertinib; Internal medicine; Hazard ratio; Placebo; Clinical endpoint; Lung cancer; Regimen; Population; Oncology; Surgery; Confidence interval; Cancer; Clinical trial; Epidermal growth factor receptor; Pathology","authors":[{"name":"Masahiro Tsuboi","is_ca":false},{"name":"Roy S. Herbst","is_ca":false},{"name":"Thomas John","is_ca":false},{"name":"Terufumi Kato","is_ca":false},{"name":"Margarita Majem","is_ca":false},{"name":"Christian Grohé","is_ca":false},{"name":"Jie Wang","is_ca":false},{"name":"Jonathan W. Goldman","is_ca":false},{"name":"Shun Lü","is_ca":false},{"name":"Wu‐Chou Su","is_ca":false},{"name":"Filippo de Marinis","is_ca":false},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Ki Hyeong Lee","is_ca":false},{"name":"Nhieu Thi Le","is_ca":false},{"name":"Arunee Dechaphunkul","is_ca":false},{"name":"Dariusz M. Kowalski","is_ca":false},{"name":"Lynne Poole","is_ca":false},{"name":"Ana Bolanos","is_ca":false},{"name":"Yuri Rukazenkov","is_ca":false},{"name":"Yi‐Long Wu","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02339926590478572,"gpt":0.3316075296963627,"spread":0.308208263791577,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001348963,0.0004339206,0.0007949766,0.0002027318,0.0001485613,0.0004039131,0.0002520997,0.000359587,0.001343933],"category_scores_gemma":[0.0008628203,0.000114376,0.001145651,0.0001593863,0.0003065016,0.0004020366,0.0002569986,0.0009032505,0.0001164769],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000510745,"about_ca_system_score_gemma":0.0004547661,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000325322,"about_ca_topic_score_gemma":0.0008020454,"domain_scores_codex":[0.999699,0.0001484789,0.00002189497,0.00004622444,0.00003423106,0.00005022115],"domain_scores_gemma":[0.9995787,0.0001135072,0.0001438707,0.00002749169,0.00001902366,0.0001175074],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7514971,0.006392879,0.03560925,0.0008503894,0.00207809,0.0001479535,0.0001710211,0.00401702,0.01316808,0.0002115148,0.002841346,0.1830153],"study_design_scores_gemma":[0.2498899,0.4670258,0.2578783,0.0003499481,0.004664729,0.0005964751,0.0001181246,0.004544987,0.007763184,0.0009443447,0.006171096,0.00005299009],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949751,0.003721593,0.0001348892,0.0002040178,0.00006480881,0.00005016115,0.0001392199,0.00001526089,0.0006950116],"genre_scores_gemma":[0.9981843,0.000973296,0.00009311528,0.0001221192,0.00006325613,0.00007530953,0.0002413111,0.000002555212,0.0002447946],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001348963,"threshold_uncertainty_score":0.00713408,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3013446577","doi":"10.1016/s0140-6736(20)30164-1","title":"Small molecules, big impact: 20 years of targeted therapy in oncology","year":2020,"lang":"en","type":"review","venue":"The Lancet","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":602,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Drug development; Drug; Precision medicine; Targeted therapy; Oncology; Bioinformatics; Cancer; Pharmacology; Internal medicine; Pathology; Biology","authors":[{"name":"Philippe L. Bédard","is_ca":true},{"name":"David M. Hyman","is_ca":false},{"name":"Matthew S. Davids","is_ca":false},{"name":"Lillian L. Siu","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1072282215240836,"gpt":0.4180433705636626,"spread":0.310815149039579,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00190725,0.001279545,0.002306281,0.001467049,0.0003305133,0.001920869,0.001236446,0.002611201,0.006640691],"category_scores_gemma":[0.002640235,0.0003059259,0.0008301112,0.001627417,0.0009611923,0.002586636,0.001181291,0.00437497,0.002747936],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001511074,"about_ca_system_score_gemma":0.00191724,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001783744,"about_ca_topic_score_gemma":0.004772302,"domain_scores_codex":[0.9994691,0.0001200634,0.00004708405,0.00006356399,0.000232222,0.00006799659],"domain_scores_gemma":[0.9984945,0.0009951899,0.000109875,0.00002871662,0.0002382008,0.0001335853],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002517193,0.00006835152,0.00007863657,0.01492708,0.0001504156,0.00009388052,0.00004601798,0.0004225891,0.001043875,0.009009625,0.1392491,0.8346588],"study_design_scores_gemma":[0.0000941225,0.000116551,0.0003230012,0.004576793,0.0001443734,0.0002426901,0.00004901094,0.0001136514,0.0001445109,0.0053714,0.9888048,0.00001920211],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003611771,0.9970301,0.00008975961,0.001329035,0.0007993575,0.00000265532,0.000021777,0.000008928446,0.0006823083],"genre_scores_gemma":[0.000534715,0.9954441,0.0001707102,0.002013196,0.0009756788,0.000007164736,0.00003648181,0.000003688663,0.0008144343],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.006640691,"threshold_uncertainty_score":0.02221537,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2168841302","doi":"10.1158/1078-0432.ccr-06-0462","title":"Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":584,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Gefitinib; Erlotinib; Epidermal growth factor receptor; Lung cancer; Medicine; Exon; Erlotinib Hydrochloride; Internal medicine; Oncology; Mutation; Point mutation; Cancer research; Cancer; Biology; Genetics; Gene","authors":[{"name":"David M. Jackman","is_ca":true},{"name":"Beow Y. Yeap","is_ca":true},{"name":"Lecia V. Sequist","is_ca":true},{"name":"Neal I. Lindeman","is_ca":false},{"name":"Alison J. Holmes","is_ca":false},{"name":"Victoria A. Joshi","is_ca":false},{"name":"Daphne W. Bell","is_ca":false},{"name":"Mark S. Huberman","is_ca":false},{"name":"Balázs Halmos","is_ca":false},{"name":"Michael S. Rabin","is_ca":true},{"name":"Daniel A. Haber","is_ca":false},{"name":"Thomas J. Lynch","is_ca":true},{"name":"Matthew Meyerson","is_ca":false},{"name":"Bruce E. Johnson","is_ca":true},{"name":"Pasi A. Jänne","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09555870628366898,"gpt":0.4421776627540716,"spread":0.3466189564704026,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003367163,0.0001738437,0.0003843608,0.000243778,0.0002832256,0.0002573694,0.0001608942,0.0003199388,0.0008525358],"category_scores_gemma":[0.00106699,0.0001310995,0.0003829481,0.0002742054,0.0002343641,0.0002093481,0.0001581553,0.0004127519,0.00010781],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001900725,"about_ca_system_score_gemma":0.0002066882,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004148324,"about_ca_topic_score_gemma":0.0009170652,"domain_scores_codex":[0.9997032,0.00007245703,0.00003601794,0.00005895475,0.00007284051,0.00005658129],"domain_scores_gemma":[0.9988875,0.0002698519,0.0005808219,0.00004118846,0.00005951049,0.0001611462],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001403429,0.0001013706,0.9877252,0.00002261998,0.000102695,0.0006850413,0.00006348009,0.0001393467,0.004982213,0.00001045114,0.00007616405,0.004687903],"study_design_scores_gemma":[0.00003089255,0.000581072,0.9954111,0.000005070525,0.00005889201,0.002745404,0.00005245332,0.0002322348,0.0006661296,0.00001422335,0.0001984461,0.000004163949],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9996884,0.0001639647,0.00002536247,0.00001667511,0.000002232486,0.000001826005,0.00002070475,0.00000121165,0.00007958034],"genre_scores_gemma":[0.9998226,0.00004347221,0.00002289584,0.00000981949,0.000005517572,0.000001942866,0.00005566404,4.767632e-7,0.00003773698],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008525358,"threshold_uncertainty_score":0.002851963,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2623725180","doi":"10.1016/s1470-2045(17)30339-x","title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":580,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ignyta; Shionogi; AstraZeneca; Associazione Italiana per la Ricerca sul Cancro; Astellas Pharma; Eli Lilly and Company","keywords":"Ceritinib; Crizotinib; Medicine; Anaplastic lymphoma kinase; Lung cancer; ALK inhibitor; Internal medicine; Chemotherapy; Oncology; Docetaxel; Pemetrexed; Gastroenterology; Cisplatin","authors":[{"name":"Alice T. Shaw","is_ca":false},{"name":"Tae Min Kim","is_ca":false},{"name":"Lucio Crinò","is_ca":false},{"name":"Cesare Gridelli","is_ca":false},{"name":"Katsuyuki Kiura","is_ca":false},{"name":"Geoffrey Liu","is_ca":true},{"name":"Silvia Novello","is_ca":false},{"name":"Alessandra Bearz","is_ca":false},{"name":"Oliver Gautschi","is_ca":false},{"name":"Tony Mok","is_ca":false},{"name":"Makoto Nishio","is_ca":false},{"name":"Giorgio V. Scagliotti","is_ca":false},{"name":"David R. Spigel","is_ca":false},{"name":"Stéphanie Deudon","is_ca":false},{"name":"Cheng Zheng","is_ca":false},{"name":"Serafino Pantano","is_ca":false},{"name":"Patrick Urban","is_ca":false},{"name":"Cristian Massacesi","is_ca":false},{"name":"Kalyanee Viraswami-Appanna","is_ca":false},{"name":"Enriqueta Felip","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04534884463340635,"gpt":0.4133336191056075,"spread":0.3679847744722012,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001640221,0.001872703,0.004238739,0.0004347755,0.0003839147,0.0011729,0.0008900173,0.00198939,0.004940008],"category_scores_gemma":[0.001681598,0.0006425027,0.00272164,0.0004682957,0.001312011,0.00150631,0.0004076943,0.003781591,0.0009418449],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001250743,"about_ca_system_score_gemma":0.001048613,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001600024,"about_ca_topic_score_gemma":0.004244637,"domain_scores_codex":[0.9993143,0.0003324719,0.00003958903,0.0001361531,0.00004147819,0.0001360732],"domain_scores_gemma":[0.9991925,0.0002300413,0.0002015714,0.00005166625,0.00003853104,0.0002857256],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9805162,0.002126752,0.0005326234,0.0006082037,0.001110608,0.0000422039,0.0000427969,0.0005551003,0.001462783,0.00009789556,0.000703813,0.01220094],"study_design_scores_gemma":[0.9334598,0.06254014,0.001772992,0.00003481716,0.0005739082,0.0000511763,0.00002686429,0.0005379058,0.0002601848,0.0001480733,0.0005772979,0.00001704742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98353,0.009738078,0.0004327325,0.0009686682,0.000851319,0.001471207,0.0006946258,0.0001700895,0.002143346],"genre_scores_gemma":[0.9909536,0.003099607,0.0005757684,0.0008770536,0.000386421,0.000945992,0.0008338797,0.00002198255,0.002305752],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004940008,"threshold_uncertainty_score":0.01652598,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2153865661","doi":"10.1200/jco.2007.14.4824","title":"Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":573,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Sanofi; AstraZeneca","keywords":"Medicine; Gefitinib; Docetaxel; Internal medicine; Performance status; Lung cancer; Interim analysis; Placebo; Chemoradiotherapy; Surgery; Oncology; Chemotherapy; Cancer; Clinical trial; Epidermal growth factor receptor; Pathology","authors":[{"name":"Karen Kelly","is_ca":true},{"name":"Kari Chansky","is_ca":true},{"name":"Laurie E. Gaspar","is_ca":true},{"name":"Kathy S. Albain","is_ca":true},{"name":"James R. Jett","is_ca":true},{"name":"Yee Ung","is_ca":true},{"name":"Derick Lau","is_ca":true},{"name":"John J. Crowley","is_ca":true},{"name":"David R. Gandara","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08398044194763006,"gpt":0.4845825549230046,"spread":0.4006021129753746,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002014423,0.002192032,0.003311165,0.0005711346,0.0006019116,0.001291877,0.0016451,0.002215042,0.005994269],"category_scores_gemma":[0.001068725,0.0006299312,0.001590925,0.0006071597,0.001698769,0.001053987,0.000397179,0.003812903,0.001629077],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001431938,"about_ca_system_score_gemma":0.002649358,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001664859,"about_ca_topic_score_gemma":0.004522889,"domain_scores_codex":[0.9995395,0.0002109571,0.00002353761,0.00008764854,0.00003939666,0.00009888293],"domain_scores_gemma":[0.9991688,0.0001199885,0.0001740844,0.00006874157,0.00003969709,0.0004287456],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9435588,0.02019645,0.001258713,0.0003952049,0.0005944128,0.00008480733,0.0001034594,0.0007327308,0.006762007,0.0001508926,0.002377574,0.02378495],"study_design_scores_gemma":[0.8725328,0.1231807,0.002081438,0.00002120499,0.0001559404,0.00006095624,0.00002073534,0.000505967,0.0007503579,0.00006672023,0.00061096,0.00001226912],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903852,0.002287841,0.0004220948,0.0006931153,0.0004261066,0.002904967,0.001063206,0.000244228,0.001573217],"genre_scores_gemma":[0.9853914,0.001446911,0.001272609,0.00106615,0.0002783258,0.004493506,0.00221564,0.00004366488,0.003792003],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005994269,"threshold_uncertainty_score":0.02005279,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4319337483","doi":"10.1016/s0140-6736(23)00221-0","title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":566,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Five Prime Therapeutics; AstraZeneca; Amgen","keywords":"Docetaxel; Medicine; Internal medicine; Oncology; Lung cancer; Cancer; Taxane; Progressive disease; Chemotherapy; Breast cancer","authors":[{"name":"Adrianus J. de Langen","is_ca":false},{"name":"Melissa L. Johnson","is_ca":false},{"name":"Julien Mazières","is_ca":false},{"name":"Anne‐Marie C. Dingemans","is_ca":false},{"name":"Giannis Mountzios","is_ca":false},{"name":"Miklos Pless","is_ca":false},{"name":"Jürgen Wolf","is_ca":false},{"name":"Martin Schüler","is_ca":false},{"name":"H. Léna","is_ca":false},{"name":"Ferdinandos Skoulidis","is_ca":false},{"name":"Yasuto Yoneshima","is_ca":false},{"name":"Sang‐We Kim","is_ca":false},{"name":"Helena Linardou","is_ca":false},{"name":"Silvia Novello","is_ca":false},{"name":"Anthonie J. van der Wekken","is_ca":false},{"name":"Yuanbin Chen","is_ca":false},{"name":"Solange Peters","is_ca":false},{"name":"Enriqueta Felip","is_ca":false},{"name":"Benjamin Solomon","is_ca":false},{"name":"Suresh S. Ramalingam","is_ca":false},{"name":"Christophe Dooms","is_ca":false},{"name":"Colin R. Lindsay","is_ca":false},{"name":"Carlos Gil Ferreira","is_ca":false},{"name":"Normand Blais","is_ca":true},{"name":"Cynthia C. Obiozor","is_ca":false},{"name":"Yang Wang","is_ca":false},{"name":"Bhakti Mehta","is_ca":false},{"name":"Tracy Varrieur","is_ca":false},{"name":"Gataree Ngarmchamnanrith","is_ca":false},{"name":"Björn Stollenwerk","is_ca":false},{"name":"David Waterhouse","is_ca":false},{"name":"Luis Paz‐Ares","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0813253911151174,"gpt":0.4193913372672951,"spread":0.3380659461521777,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001440557,0.002233088,0.003523941,0.0004088082,0.0004425968,0.00148892,0.0009535962,0.002047943,0.008540268],"category_scores_gemma":[0.001627345,0.0007588429,0.003285429,0.0004525798,0.001356957,0.001504307,0.0004304477,0.005124176,0.001516565],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001248798,"about_ca_system_score_gemma":0.001113681,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001793847,"about_ca_topic_score_gemma":0.005616664,"domain_scores_codex":[0.999465,0.0002526239,0.00002579501,0.0001044808,0.0000423645,0.0001097425],"domain_scores_gemma":[0.9993334,0.0002039029,0.0001301151,0.00004493956,0.00003941747,0.0002481222],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.970347,0.00319976,0.0003684252,0.0009485674,0.001487402,0.00005504678,0.00007177701,0.0007830306,0.002202845,0.0002611271,0.001791872,0.01848304],"study_design_scores_gemma":[0.9558786,0.0408876,0.0008100981,0.00005375468,0.0004525618,0.00003859189,0.00003318888,0.0004249927,0.0001866763,0.0003216382,0.000892339,0.0000198792],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9710958,0.01261399,0.001068679,0.002133438,0.002227978,0.003974186,0.00216776,0.0002399658,0.004478258],"genre_scores_gemma":[0.9749703,0.006611275,0.00149514,0.0022144,0.0005691793,0.003427084,0.001619166,0.00006101848,0.009032479],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008540268,"threshold_uncertainty_score":0.02857006,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2587420003","doi":"10.1093/annonc/mdw611","title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":522,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"Chugai Pharmaceutical; Genentech; Ono Pharmaceutical; Astellas Pharma; Chinese University of Hong Kong; GlaxoSmithKline; AstraZeneca Korea; Clovis Oncology; Vertex Pharmaceuticals; International Association for the Study of Lung Cancer; Amgen; ACEA Biosciences; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Gefitinib; Afatinib; Medicine; Internal medicine; Lung cancer; Hazard ratio; Oncology; Epidermal growth factor receptor; T790M; Proportional hazards model; Gastroenterology; Confidence interval; Cancer","authors":[{"name":"Luis Paz‐Ares","is_ca":false},{"name":"E.H. Tan","is_ca":false},{"name":"Kenneth J. O’Byrne","is_ca":false},{"name":"L. Zhang","is_ca":false},{"name":"Vera Hirsh","is_ca":true},{"name":"Michael Boyer","is_ca":false},{"name":"James Chih‐Hsin Yang","is_ca":false},{"name":"Tony Mok","is_ca":false},{"name":"K.H. Lee","is_ca":false},{"name":"Shun Lü","is_ca":false},{"name":"Yajun Shi","is_ca":false},{"name":"D. H. Lee","is_ca":false},{"name":"Janessa Laskin","is_ca":true},{"name":"D.-W. Kim","is_ca":false},{"name":"Scott A. Laurie","is_ca":true},{"name":"Karl Kölbeck","is_ca":false},{"name":"Jean Fan","is_ca":false},{"name":"Nigel Dodd","is_ca":false},{"name":"Angela Märten","is_ca":false},{"name":"K. Park","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08223081129384406,"gpt":0.4570319687057121,"spread":0.374801157411868,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001942383,0.001186464,0.002936839,0.0002988515,0.0003782531,0.00136666,0.0006495397,0.001220256,0.002316322],"category_scores_gemma":[0.00196096,0.0003112297,0.003425864,0.000466929,0.0008407968,0.001739359,0.0003765004,0.003161561,0.0005156103],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001126021,"about_ca_system_score_gemma":0.0008270071,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001162888,"about_ca_topic_score_gemma":0.004860464,"domain_scores_codex":[0.9991938,0.0004050804,0.00006633416,0.0001181352,0.00006369178,0.0001529089],"domain_scores_gemma":[0.9991411,0.0002600115,0.0002391707,0.00006149637,0.00005738776,0.0002407749],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8252606,0.00219553,0.01354863,0.00236594,0.008695457,0.0002200778,0.0002048985,0.004875617,0.005319493,0.0005847111,0.008985129,0.1277438],"study_design_scores_gemma":[0.7642097,0.1311206,0.07346746,0.0003783233,0.009674823,0.00107826,0.0004514144,0.004586832,0.002051845,0.002847899,0.009973552,0.0001593254],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9710215,0.02166194,0.0002980435,0.001797851,0.000384098,0.0002045179,0.001263723,0.00008102508,0.003287328],"genre_scores_gemma":[0.991056,0.004427063,0.0002803992,0.0008491898,0.0002223617,0.0001495104,0.001755508,0.00002076486,0.001239192],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002936839,"threshold_uncertainty_score":0.01027244,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1979840121","doi":"10.1002/ijc.27339","title":"Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case–control studies","year":2011,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":503,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Institut National de la Recherche Scientifique; Université de Montréal","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Lung cancer; Medicine; Cancer; Relative risk; Lung; Case-control study; Cigarette smoking; Environmental health; Oncology; Internal medicine; Pathology; Confidence interval","authors":[{"name":"Beate Pesch","is_ca":false},{"name":"Benjamin Kendzia","is_ca":false},{"name":"Per Gustavsson","is_ca":false},{"name":"Karl‐Heinz Jöckel","is_ca":false},{"name":"Georg Johnen","is_ca":false},{"name":"Hermann Pohlabeln","is_ca":false},{"name":"Ann Olsson","is_ca":false},{"name":"Wolfgang Ahrens","is_ca":false},{"name":"Isabelle Groß","is_ca":false},{"name":"Irene Brüske","is_ca":false},{"name":"Heinz‐Erich Wichmann","is_ca":false},{"name":"Franco Merletti","is_ca":false},{"name":"Lorenzo Richiardi","is_ca":false},{"name":"Lorenzo Simonato","is_ca":false},{"name":"Cristina Fortes","is_ca":false},{"name":"Jack Siemiatycki","is_ca":true},{"name":"Marie‐Elise Parent","is_ca":true},{"name":"Dario Consonni","is_ca":false},{"name":"Maria Teresa Landi","is_ca":false},{"name":"Neil E. Caporaso","is_ca":false},{"name":"David Zaridze","is_ca":false},{"name":"Adrian Cassidy","is_ca":false},{"name":"Neonila Szeszenia‐Dąbrowska","is_ca":false},{"name":"Péter Rudnai","is_ca":false},{"name":"Jolanta Lissowska","is_ca":false},{"name":"Isabelle Stücker","is_ca":false},{"name":"Eleonóra Fabiánová","is_ca":false},{"name":"Rodica Stanescu Dumitru","is_ca":false},{"name":"Vladimír Bencko","is_ca":false},{"name":"Lenka Foretová","is_ca":false},{"name":"Vladimí­r Janout","is_ca":false},{"name":"Charles M. Rudin","is_ca":false},{"name":"Paul Brennan","is_ca":false},{"name":"Paolo Boffetta","is_ca":false},{"name":"Kurt Straíf","is_ca":false},{"name":"Thomas Brüning","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03076127353565602,"gpt":0.3906267141087815,"spread":0.3598654405731255,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03198367,0.003335111,0.01007931,0.01266281,0.0005025345,0.002591629,0.002057898,0.001999116,0.002739512],"category_scores_gemma":[0.04570428,0.002175638,0.0398392,0.009406216,0.0005762749,0.001536461,0.001982015,0.001810493,0.0003870944],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008596003,"about_ca_system_score_gemma":0.0007094699,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00715414,"about_ca_topic_score_gemma":0.005941404,"domain_scores_codex":[0.9706312,0.01583711,0.005675713,0.00517598,0.002153866,0.000526083],"domain_scores_gemma":[0.9685239,0.02051764,0.005044149,0.003918537,0.001685154,0.0003104819],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.004504532,0.00002429272,0.07553726,0.01006806,0.8982152,0.0002002359,0.0000767477,0.001643885,0.0007488556,0.0002200261,0.0008515121,0.007909507],"study_design_scores_gemma":[0.0009352422,0.0006081499,0.1107563,0.001581592,0.8774585,0.0005394414,0.0001298737,0.002539599,0.0004860946,0.000977314,0.003892673,0.00009511268],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.188203,0.750104,0.03762303,0.0005945524,0.001049172,0.001072002,0.0186851,0.0006263005,0.002043003],"genre_scores_gemma":[0.9018674,0.06851403,0.01399109,0.0005831093,0.0006479031,0.002442001,0.01056922,0.0002475974,0.001137691],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.03198367,"threshold_uncertainty_score":0.1691478,"prediction_status":"machine_predicted_unvalidated"},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"meta_analysis","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"meta_analysis","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2104748005","doi":"10.1200/jco.2009.24.3030","title":"Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":492,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Gefitinib; Docetaxel; Medicine; Lung cancer; Oncology; Internal medicine; Biomarker; Hazard ratio; Epidermal growth factor receptor; KRAS; Cancer; Confidence interval; Biology; Colorectal cancer","authors":[{"name":"Jean‐Yves Douillard","is_ca":true},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Vera Hirsh","is_ca":true},{"name":"Tony Mok","is_ca":true},{"name":"Mark A. Socinski","is_ca":true},{"name":"Radj Gervais","is_ca":true},{"name":"Mei‐Lin Liao","is_ca":true},{"name":"Helge Bischoff","is_ca":true},{"name":"Martin Reck","is_ca":true},{"name":"Mark V. Sellers","is_ca":true},{"name":"Claire Watkins","is_ca":true},{"name":"Georgina Speake","is_ca":true},{"name":"Alison Armour","is_ca":true},{"name":"Edward S. Kim","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1212243943653459,"gpt":0.490069456183446,"spread":0.3688450618181001,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004019459,0.0007160379,0.001627632,0.0002321809,0.0002563594,0.0008311191,0.0005756865,0.0008288082,0.001326755],"category_scores_gemma":[0.003399608,0.0002294454,0.001796056,0.000321167,0.0007003933,0.0006458308,0.000267391,0.001317369,0.0002194961],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007452452,"about_ca_system_score_gemma":0.0007119651,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007406171,"about_ca_topic_score_gemma":0.001748868,"domain_scores_codex":[0.9983943,0.001103005,0.00009919783,0.0001743635,0.0001203095,0.0001088767],"domain_scores_gemma":[0.9969087,0.001072034,0.001051449,0.0002342933,0.0001224963,0.0006109776],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9272063,0.002693864,0.04129811,0.0003089435,0.00270658,0.00005858679,0.0000470347,0.001347392,0.001955108,0.0001163588,0.0011913,0.02107045],"study_design_scores_gemma":[0.602308,0.1483404,0.2334052,0.0001199087,0.00603695,0.0003012393,0.00009538574,0.003998077,0.002008289,0.0005108843,0.002799426,0.00007629891],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949666,0.003199431,0.0001729848,0.0002640204,0.00007525808,0.0001899449,0.0006321578,0.00001852262,0.0004810616],"genre_scores_gemma":[0.9962814,0.0008788065,0.0002725756,0.000261405,0.0001443414,0.0002683543,0.001513734,0.000008293525,0.000370996],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004019459,"threshold_uncertainty_score":0.02125716,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2925139051","doi":"10.1016/j.jtho.2019.03.007","title":"Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":491,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Merck Sharp and Dohme; Genentech; F. Hoffmann-La Roche; Amgen; Ariad Pharmaceuticals; Roche; Novartis; Celgene; Bristol-Myers Squibb; AstraZeneca; Pfizer; AbbVie; Merck","keywords":"Alectinib; Medicine; Lung cancer; Crizotinib; Oncology; Internal medicine; Cancer research","authors":[{"name":"D. Ross Camidge","is_ca":false},{"name":"Rafał Dziadziuszko","is_ca":false},{"name":"Solange Peters","is_ca":false},{"name":"Tony Mok","is_ca":false},{"name":"Johannes Noé","is_ca":false},{"name":"Małgorzata Nowicka","is_ca":false},{"name":"Shirish M. Gadgeel","is_ca":false},{"name":"Parneet Cheema","is_ca":true},{"name":"Nick Pavlakis","is_ca":false},{"name":"Filippo de Marinis","is_ca":false},{"name":"Byoung Chul Cho","is_ca":false},{"name":"Li Zhang","is_ca":false},{"name":"Denis Moro‐Sibilot","is_ca":false},{"name":"Ting Liu","is_ca":false},{"name":"Walter Bordogna","is_ca":false},{"name":"Bogdana Balas","is_ca":false},{"name":"Bárbara Müller","is_ca":false},{"name":"Alice T. Shaw","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01789835229157475,"gpt":0.4489390676521736,"spread":0.4310407153605988,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007501107,0.0009114631,0.001700021,0.0003653186,0.0001805525,0.001222503,0.000734945,0.0004877313,0.00154758],"category_scores_gemma":[0.003587858,0.0002678644,0.002861666,0.0006999576,0.0007047034,0.000702725,0.0005882403,0.00129399,0.0003053268],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000706878,"about_ca_system_score_gemma":0.0009269101,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006505412,"about_ca_topic_score_gemma":0.002289759,"domain_scores_codex":[0.9978673,0.001242706,0.0001247261,0.0002378494,0.0003861384,0.0001411048],"domain_scores_gemma":[0.9966471,0.001071871,0.00136733,0.0003942522,0.0002640089,0.0002554735],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.625515,0.00223409,0.1596321,0.002770374,0.03154852,0.0004203648,0.0003932529,0.009940762,0.0174168,0.0007343457,0.0107769,0.1386174],"study_design_scores_gemma":[0.191763,0.09718373,0.6363362,0.0004097001,0.0385906,0.001318068,0.0002270315,0.004129115,0.007458234,0.001525886,0.02086793,0.0001904487],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9833089,0.007621725,0.0006028656,0.0005005196,0.00006953697,0.0002690251,0.00473138,0.00006112231,0.002835018],"genre_scores_gemma":[0.986105,0.002202736,0.000580917,0.0006059156,0.0001211382,0.0001981968,0.009409739,0.00003231135,0.0007440128],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007501107,"threshold_uncertainty_score":0.03967011,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2295354328","doi":"10.1016/s1470-2045(15)00614-2","title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":470,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ignyta; National Institutes of Health; University of Washington; Astex Pharmaceuticals; Eli Lilly and Company; Novartis Institutes for BioMedical Research; Ariad Pharmaceuticals; Genentech; Pfizer; Novartis Pharmaceuticals Corporation; Chugai Pharmaceutical; Servier; Universität Heidelberg","keywords":"Ceritinib; Crizotinib; Medicine; ALK inhibitor; Internal medicine; Anaplastic lymphoma kinase; Lung cancer; Oncology; Tyrosine-kinase inhibitor; Clinical trial; Cancer","authors":[{"name":"Dong‐Wan Kim","is_ca":false},{"name":"Ranee Mehra","is_ca":false},{"name":"Daniel S.W. Tan","is_ca":false},{"name":"Enriqueta Felip","is_ca":false},{"name":"Laura Q.M. Chow","is_ca":false},{"name":"D. Ross Camidge","is_ca":false},{"name":"Johan Vansteenkiste","is_ca":false},{"name":"Sunil Sharma","is_ca":false},{"name":"Tommaso De Pas","is_ca":false},{"name":"Gregory J. Riely","is_ca":false},{"name":"Benjamin Solomon","is_ca":false},{"name":"Jürgen Wolf","is_ca":false},{"name":"Michael Thomas","is_ca":false},{"name":"Martin Schüler","is_ca":false},{"name":"Geoffrey Liu","is_ca":true},{"name":"Armando Santoro","is_ca":false},{"name":"Santosh Sutradhar","is_ca":false},{"name":"Siyu Li","is_ca":false},{"name":"Tomasz Szczudlo","is_ca":false},{"name":"A. Yovine","is_ca":false},{"name":"Alice T. Shaw","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04046967010096525,"gpt":0.3862219429664884,"spread":0.3457522728655231,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003031051,0.001226548,0.002963015,0.0003539024,0.0003035282,0.001207069,0.0007081483,0.001309749,0.002192087],"category_scores_gemma":[0.002645606,0.0003669455,0.003056121,0.0004350575,0.0007380106,0.001715413,0.0003055554,0.003054186,0.0004606333],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001114125,"about_ca_system_score_gemma":0.0006733339,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006678578,"about_ca_topic_score_gemma":0.002456298,"domain_scores_codex":[0.9991541,0.0003807857,0.00006431372,0.0001568422,0.0001186147,0.0001252742],"domain_scores_gemma":[0.9983461,0.0005648005,0.0005948362,0.0001056642,0.0001225751,0.0002660388],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7273095,0.003201728,0.01596294,0.003908011,0.01020954,0.0001850101,0.0002222714,0.004605023,0.01020618,0.000412207,0.01044752,0.21333],"study_design_scores_gemma":[0.6735234,0.1895769,0.1005252,0.000449734,0.01114412,0.001278118,0.000185766,0.002928129,0.0048647,0.001416998,0.01392567,0.0001813646],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9529435,0.03831324,0.0005601856,0.001309927,0.0004222483,0.0004272729,0.002598141,0.0001689789,0.003256598],"genre_scores_gemma":[0.9885972,0.005591814,0.0004890693,0.0008191311,0.0002917338,0.0001756308,0.002888914,0.00003508889,0.001111609],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003031051,"threshold_uncertainty_score":0.01602989,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2138200001","doi":"10.1016/j.jmoldx.2013.03.001","title":"Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors","year":2013,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":461,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Guideline; Anaplastic lymphoma kinase; Medicine; Lung cancer; Family medicine; Oncology; Internal medicine; Epidermal growth factor receptor; Cancer; Pathology","authors":[{"name":"Neal I. Lindeman","is_ca":false},{"name":"Philip T. Cagle","is_ca":false},{"name":"Mary Beth Beasley","is_ca":false},{"name":"Dhananjay Chitale","is_ca":false},{"name":"Sanja Đačić","is_ca":false},{"name":"Giuseppe Giaccone","is_ca":false},{"name":"Robert B. Jenkins","is_ca":false},{"name":"David J. Kwiatkowski","is_ca":false},{"name":"Juan‐Sebastian Saldivar","is_ca":false},{"name":"Jeremy A. Squire","is_ca":true},{"name":"Erik Thunnissen","is_ca":false},{"name":"Marc Ladanyi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009204737053342864,"gpt":0.3159489873506346,"spread":0.3067442502972917,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002805911,0.0007642147,0.001202747,0.002355275,0.0008877512,0.001356066,0.002217209,0.003910458,0.004506557],"category_scores_gemma":[0.007862678,0.000357813,0.00200662,0.001044204,0.000407268,0.0007354403,0.0009198595,0.003622945,0.003001274],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001603827,"about_ca_system_score_gemma":0.004051543,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01079241,"about_ca_topic_score_gemma":0.01376179,"domain_scores_codex":[0.9978845,0.0005070372,0.0006832675,0.0001489528,0.0005503312,0.0002259903],"domain_scores_gemma":[0.9938363,0.001690624,0.0005503,0.000129291,0.003081193,0.0007122158],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004154949,0.0006398202,0.08121683,0.0007553279,0.0001932395,0.008341189,0.0005184309,0.003918335,0.01150581,0.005953691,0.6846837,0.2018582],"study_design_scores_gemma":[0.0005778706,0.001145271,0.2102534,0.007919547,0.0008605384,0.03207404,0.001576299,0.01548722,0.01202885,0.01422355,0.7036262,0.0002271149],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.09823719,0.05488686,0.1116998,0.4924269,0.007795036,0.005989237,0.01976883,0.003928995,0.2052672],"genre_scores_gemma":[0.4454501,0.03627124,0.2867492,0.1388525,0.006406041,0.005690621,0.03621387,0.0006642977,0.04370201],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.01079241,"threshold_uncertainty_score":0.02145916,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137043950","doi":"10.1016/s1470-2045(15)00006-6","title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":434,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa","funders":"AstraZeneca; Eli Lilly and Company","keywords":"Afatinib; Erlotinib; Medicine; Clinical endpoint; Internal medicine; Lung cancer; Erlotinib Hydrochloride; Oncology; Population; Randomized controlled trial; Surgery; Cancer; Epidermal growth factor receptor","authors":[{"name":"Jean‐Charles Soria","is_ca":false},{"name":"Enriqueta Felip","is_ca":false},{"name":"Manuel Cobo","is_ca":false},{"name":"Shun Lü","is_ca":false},{"name":"Konstantinos Syrigos","is_ca":false},{"name":"Ki Hyeong Lee","is_ca":false},{"name":"Erdem Göker","is_ca":false},{"name":"Vassilis Georgoulias","is_ca":false},{"name":"Wěi Li","is_ca":false},{"name":"Dolores Isla","is_ca":false},{"name":"Salih Zeki Güçlü","is_ca":false},{"name":"Alessandro Morabito","is_ca":false},{"name":"Young Joo Min","is_ca":false},{"name":"Andrea Ardizzoni","is_ca":false},{"name":"Shirish M. Gadgeel","is_ca":false},{"name":"Bushi Wang","is_ca":false},{"name":"Vikram K. Chand","is_ca":false},{"name":"Glenwood Goss","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06509205628352367,"gpt":0.4127227631918144,"spread":0.3476307069082907,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001807102,0.002680914,0.004671586,0.0004890463,0.0005336893,0.001841977,0.001391932,0.002832984,0.009406119],"category_scores_gemma":[0.002092127,0.000886453,0.004287839,0.0004602956,0.001435429,0.002295659,0.0005452673,0.005324584,0.001882992],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001157637,"about_ca_system_score_gemma":0.001023388,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001297768,"about_ca_topic_score_gemma":0.003116689,"domain_scores_codex":[0.9992419,0.0003441798,0.00004814951,0.0001637515,0.00004753303,0.0001545417],"domain_scores_gemma":[0.9990944,0.0002598149,0.000182455,0.00007812211,0.00006246873,0.0003227743],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9830086,0.002986166,0.0002770238,0.0006087224,0.001040368,0.00004006912,0.00004522492,0.0003827605,0.00119679,0.00009982295,0.0007862083,0.009528244],"study_design_scores_gemma":[0.9689375,0.02922716,0.0005182039,0.00002604131,0.0003372163,0.00003366768,0.00002028755,0.0002791283,0.0001131935,0.0001477926,0.0003453577,0.00001450546],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9795583,0.008396246,0.000806301,0.001490602,0.001477446,0.003311779,0.001707445,0.0002338463,0.003018086],"genre_scores_gemma":[0.9833922,0.003516605,0.001270921,0.001407937,0.0005916456,0.003289349,0.001444992,0.00004142492,0.005045],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009406119,"threshold_uncertainty_score":0.0314666,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2514360855","doi":"10.5858/arpa.2012-0720-oa","title":"Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology","year":2013,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":428,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Guideline; Medicine; Anaplastic lymphoma kinase; Lung cancer; Family medicine; Oncology; Internal medicine; Pathology","authors":[{"name":"Neal I. Lindeman","is_ca":false},{"name":"Philip T. Cagle","is_ca":false},{"name":"Mary Beth Beasley","is_ca":false},{"name":"Dhananjay Chitale","is_ca":false},{"name":"Sanja Đačić","is_ca":false},{"name":"Giuseppe Giaccone","is_ca":false},{"name":"Robert B. Jenkins","is_ca":false},{"name":"David J. Kwiatkowski","is_ca":false},{"name":"Juan‐Sebastian Saldivar","is_ca":false},{"name":"Jeremy A. Squire","is_ca":true},{"name":"Erik Thunnissen","is_ca":false},{"name":"Marc Ladanyi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009531255861994709,"gpt":0.3332404848885003,"spread":0.3237092290265056,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01754583,0.001944933,0.002998631,0.006738125,0.001632646,0.003110694,0.008619254,0.01181324,0.006288239],"category_scores_gemma":[0.04517565,0.001404301,0.005815569,0.005157174,0.00137002,0.003680051,0.002776501,0.01031906,0.008579781],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006387461,"about_ca_system_score_gemma":0.02565541,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02596559,"about_ca_topic_score_gemma":0.0354079,"domain_scores_codex":[0.9780873,0.007795128,0.00640626,0.0008460922,0.005986064,0.0008789958],"domain_scores_gemma":[0.9480011,0.0102532,0.005612972,0.0006771081,0.03345773,0.001997892],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009770095,0.0001914496,0.001593453,0.007285846,0.0002122054,0.0004791325,0.0004357117,0.0009314194,0.001029782,0.002931828,0.8798494,0.1049621],"study_design_scores_gemma":[0.0007291659,0.0002555079,0.009902607,0.0680486,0.001130858,0.001807912,0.0006524579,0.001805243,0.0009783023,0.008113074,0.9063663,0.0002098746],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.006041616,0.1832577,0.04860896,0.6055767,0.01966553,0.01768354,0.02007858,0.001917333,0.09717003],"genre_scores_gemma":[0.03589069,0.2171774,0.3701884,0.2440738,0.008077657,0.02910146,0.04997326,0.0005587612,0.04495861],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.02596559,"threshold_uncertainty_score":0.09279233,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1814699096","doi":"10.1016/j.ctrv.2004.08.002","title":"Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer☆☆☆☆Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.","year":2004,"lang":"en","type":"letter","venue":"Cancer Treatment Reviews","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":406,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Gefitinib; Medicine; Carboplatin; Paclitaxel; Lung cancer; Chemotherapy; Oncology; Internal medicine; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Cancer; Cisplatin","authors":[{"name":"William K. Evans","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01463295194877606,"gpt":0.3232133757697233,"spread":0.3085804238209472,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001246814,0.0003132203,0.001721479,0.0003788235,0.0007962468,0.0007693553,0.0004215174,0.006538305,0.00564177],"category_scores_gemma":[0.006467468,0.0001718835,0.001021508,0.0005402566,0.0004916405,0.0008104823,0.0002685315,0.003045108,0.002444633],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001413378,"about_ca_system_score_gemma":0.0007990158,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001859429,"about_ca_topic_score_gemma":0.006921879,"domain_scores_codex":[0.999143,0.000272284,0.0001011821,0.00009659019,0.0002226628,0.0001642992],"domain_scores_gemma":[0.997976,0.001208307,0.0002116145,0.00004387111,0.0002409625,0.0003192183],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.007932032,0.0002888511,0.022985,0.0009970178,0.000482382,0.01199439,0.0001861167,0.0003627307,0.003457135,0.001477554,0.6500162,0.2998206],"study_design_scores_gemma":[0.008840526,0.006486249,0.09236597,0.001436707,0.00169951,0.02583051,0.0004676285,0.001631676,0.002900948,0.005463522,0.8527438,0.0001329384],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.06086035,0.07834439,0.0003028211,0.8030335,0.02061971,0.00008109231,0.001143321,0.0002154438,0.03539935],"genre_scores_gemma":[0.3479258,0.05097986,0.0007114542,0.4955959,0.07821374,0.0001764536,0.0008246801,0.00009931347,0.02547283],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.006538305,"threshold_uncertainty_score":0.01887357,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4387882142","doi":"10.1016/j.annonc.2023.10.117","title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":396,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre; BC Cancer Agency","funders":"Daiichi Sankyo Europe; Gilead Sciences; National Cancer Institute; American College of Radiology Imaging Network; Society for Immunotherapy of Cancer; Pfizer Japan; Genentech; Mirati Therapeutics; Jounce Therapeutics; Chugai Pharmaceutical; MSD K.K.; Jazz Pharmaceuticals; Eli Lilly Japan; ECOG-ACRIN Cancer Research Group; Janssen Biotech; Helsinn; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Janssen Research and Development; EMD Serono; International Association for the Study of Lung Cancer; Sanofi; Amgen; Pfizer","keywords":"Medicine; Carboplatin; Chemotherapy; Internal medicine; Pemetrexed; Oncology; Chemotherapy regimen; Lung cancer; Hazard ratio; Osimertinib; Regimen; Progression-free survival; Phases of clinical research; Cancer; Cisplatin; Erlotinib; Epidermal growth factor receptor; Confidence interval","authors":[{"name":"Antonio Passaro","is_ca":false},{"name":"Jing Wang","is_ca":false},{"name":"Yan Wang","is_ca":false},{"name":"S.-H. Lee","is_ca":false},{"name":"Barbara Melosky","is_ca":true},{"name":"Jin‐Yuan Shih","is_ca":false},{"name":"K. Azuma","is_ca":false},{"name":"Óscar Juan","is_ca":false},{"name":"Manuel Cobo","is_ca":false},{"name":"Enriqueta Felip","is_ca":false},{"name":"Nicolas Girard","is_ca":false},{"name":"Alexis B. Cortot","is_ca":false},{"name":"Raffaele Califano","is_ca":false},{"name":"Federico Cappuzzo","is_ca":false},{"name":"Scott Owen","is_ca":true},{"name":"Sanjay Popat","is_ca":false},{"name":"Ju Le Tan","is_ca":false},{"name":"Jorge Salinas","is_ca":false},{"name":"Pascale Tomasini","is_ca":false},{"name":"Ryan D. Gentzler","is_ca":false},{"name":"William N. William","is_ca":false},{"name":"Karen L. Reckamp","is_ca":false},{"name":"Toshiaki Takahashi","is_ca":false},{"name":"Sandip Ganguly","is_ca":false},{"name":"Dariusz M. Kowalski","is_ca":false},{"name":"Alessandra Bearz","is_ca":false},{"name":"Melanie Mackean","is_ca":false},{"name":"P. Barala","is_ca":false},{"name":"Ariel B. Bourla","is_ca":false},{"name":"Angela Girvin","is_ca":false},{"name":"James Greger","is_ca":false},{"name":"Dawn Millington","is_ca":false},{"name":"Monica Withelder","is_ca":false},{"name":"John Xie","is_ca":false},{"name":"Tao Sun","is_ca":false},{"name":"Shalin Shah","is_ca":false},{"name":"B. Diorio","is_ca":false},{"name":"Roland E. Knoblauch","is_ca":false},{"name":"Joshua Bauml","is_ca":false},{"name":"Rosario García Campelo","is_ca":false},{"name":"Byoung Chul Cho","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03675421611862686,"gpt":0.4300967680827514,"spread":0.3933425519641245,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002013437,0.001270901,0.00182608,0.0003988167,0.0002654324,0.0009389222,0.0006677229,0.0007543507,0.001754431],"category_scores_gemma":[0.0008833421,0.0004083832,0.00188704,0.0003844203,0.0007129812,0.000785239,0.0003086557,0.002345682,0.0003931198],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008775276,"about_ca_system_score_gemma":0.001139904,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007171694,"about_ca_topic_score_gemma":0.002464771,"domain_scores_codex":[0.9995885,0.0002130845,0.00002708515,0.00006265951,0.00004279055,0.00006590124],"domain_scores_gemma":[0.999329,0.0001434516,0.0001452014,0.00005353084,0.00003181039,0.0002969929],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8588868,0.03062177,0.01074895,0.0007793661,0.003249476,0.0001469107,0.0001907771,0.001745843,0.01676963,0.0001368879,0.001796055,0.07492759],"study_design_scores_gemma":[0.5528408,0.4065684,0.03045716,0.00007928099,0.002598305,0.0002746813,0.00006930803,0.001347148,0.003433614,0.0001866316,0.002107574,0.00003707797],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955914,0.00275618,0.0001499903,0.0001581119,0.00006014439,0.0003596093,0.0002779492,0.00002319697,0.0006233572],"genre_scores_gemma":[0.994212,0.002439301,0.0004263915,0.0003409479,0.0001509175,0.0004912633,0.001035654,0.00001602902,0.0008876228],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002013437,"threshold_uncertainty_score":0.01064819,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1837617056","doi":"","title":"Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":389,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Epidermal growth factor receptor; Cancer research; Autophosphorylation; Receptor tyrosine kinase; Tyrosine kinase; Epidermal growth factor; GRB2; Tropomyosin receptor kinase C; Growth factor receptor; Platelet-derived growth factor receptor; Gefitinib; ROR1; Biology; Signal transduction; Growth factor receptor inhibitor; Medicine; Cell biology; Internal medicine; Cancer; Receptor; Growth factor; Kinase; Protein kinase A","authors":[{"name":"Gillian Bethune","is_ca":true},{"name":"Drew Bethune","is_ca":false},{"name":"Neale D. Ridgway","is_ca":false},{"name":"Zhaolin Xu","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02782150552786074,"gpt":0.3281403449556285,"spread":0.3003188394277678,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000636668,0.0007863093,0.001074242,0.001950849,0.0002261004,0.0008402915,0.0008877593,0.001197305,0.00602413],"category_scores_gemma":[0.0007550724,0.0001843024,0.0004334385,0.002103066,0.0002319917,0.001423534,0.0004448983,0.001435023,0.004547396],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003302176,"about_ca_system_score_gemma":0.0007832409,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001360989,"about_ca_topic_score_gemma":0.004178982,"domain_scores_codex":[0.9998181,0.00002929823,0.00003422401,0.00002369622,0.00007021683,0.00002451634],"domain_scores_gemma":[0.9995428,0.0001488085,0.00005742441,0.00001115295,0.0001489665,0.00009082765],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001444656,0.0000964699,0.001368871,0.003657684,0.00008766771,0.001005247,0.00004543195,0.0001259065,0.0006881075,0.0005487503,0.09282104,0.8994104],"study_design_scores_gemma":[0.00004544191,0.0001824747,0.003735179,0.001526621,0.0002656369,0.009638778,0.00007778218,0.0001090125,0.0002853088,0.0006205031,0.9834954,0.00001783364],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004442104,0.9948245,0.000237014,0.001108475,0.001053771,0.000007465054,0.00005827915,0.00002055208,0.002245775],"genre_scores_gemma":[0.002045296,0.9906184,0.0007933215,0.001105286,0.00179042,0.00001510973,0.0002697128,0.000003980088,0.003358479],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00602413,"threshold_uncertainty_score":0.02015269,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4318693852","doi":"10.1200/jco.22.02186","title":"Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":389,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; AstraZeneca","keywords":"Medicine; Afatinib; Clinical endpoint; Internal medicine; Oncology; Osimertinib; Lung cancer; Hazard ratio; Cancer; Clinical trial; Stage (stratigraphy); Adenocarcinoma; Confidence interval; Erlotinib; Epidermal growth factor receptor","authors":[{"name":"Roy S. Herbst","is_ca":false},{"name":"Yi‐Long Wu","is_ca":false},{"name":"Thomas John","is_ca":false},{"name":"Christian Grohé","is_ca":false},{"name":"Margarita Majem","is_ca":false},{"name":"Jie Wang","is_ca":false},{"name":"Terufumi Kato","is_ca":false},{"name":"Jonathan W. Goldman","is_ca":false},{"name":"К. К. Лактионов","is_ca":false},{"name":"Sang‐We Kim","is_ca":false},{"name":"Chong‐Jen Yu","is_ca":false},{"name":"Hữu Vĩnh Vũ","is_ca":false},{"name":"Shun Lü","is_ca":false},{"name":"Kye Young Lee","is_ca":false},{"name":"Guzel Mukhametshina","is_ca":false},{"name":"Charuwan Akewanlop","is_ca":false},{"name":"Filippo de Marinis","is_ca":false},{"name":"Laura Bonanno","is_ca":false},{"name":"Manuel Dómine","is_ca":false},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Damien Urban","is_ca":false},{"name":"Xiangning Huang","is_ca":false},{"name":"Ana Bolanos","is_ca":true},{"name":"Marta Stachowiak","is_ca":false},{"name":"Masahiro Tsuboi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1084029731460099,"gpt":0.5189698770640995,"spread":0.4105669039180896,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01099146,0.001157071,0.002372448,0.0005244666,0.0003329028,0.001250963,0.0006607198,0.0007117833,0.002944604],"category_scores_gemma":[0.005292097,0.0004487956,0.002699432,0.0007062494,0.000572626,0.0009492388,0.0003848812,0.002235918,0.0005120263],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005666292,"about_ca_system_score_gemma":0.001328733,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007034809,"about_ca_topic_score_gemma":0.00282966,"domain_scores_codex":[0.9962788,0.002747833,0.0002125078,0.000198101,0.0003891496,0.0001735555],"domain_scores_gemma":[0.9970574,0.001149757,0.001045994,0.0002665804,0.0002287547,0.0002514941],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8066642,0.005719726,0.009638718,0.002713992,0.00710055,0.00008941654,0.0001975913,0.001851958,0.006570023,0.0006506802,0.01011522,0.1486877],"study_design_scores_gemma":[0.8041613,0.1139385,0.04052779,0.0004543133,0.01397036,0.0002496685,0.0001069362,0.00207714,0.003118172,0.0008592094,0.02044334,0.00009330994],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9320486,0.03648473,0.004046806,0.002657985,0.0009084736,0.00587705,0.01027898,0.0002010933,0.007496344],"genre_scores_gemma":[0.9472024,0.01663206,0.008352847,0.002919956,0.001390389,0.006381709,0.01198285,0.00009770562,0.005040138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01099146,"threshold_uncertainty_score":0.05812913,"prediction_status":"machine_predicted_unvalidated"},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2126372889","doi":"10.1158/1078-0432.ccr-06-2610","title":"Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":383,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Rash; Erlotinib; Internal medicine; Medicine; Gefitinib; Gemcitabine; Epidermal growth factor receptor; Erlotinib Hydrochloride; Hazard ratio; Gastroenterology; Oncology; Cancer; Confidence interval","authors":[{"name":"Bret Wacker","is_ca":false},{"name":"Tina Nagrani","is_ca":false},{"name":"Jacqueline Weinberg","is_ca":false},{"name":"Karsten Witt","is_ca":false},{"name":"Gary M. Clark","is_ca":false},{"name":"Pablo J. Cagnoni","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1488288453879716,"gpt":0.5328739408514896,"spread":0.3840450954635181,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0233627,0.0006081443,0.002005009,0.0005904169,0.0004309462,0.001489215,0.000640992,0.000904542,0.0009603868],"category_scores_gemma":[0.02004947,0.0004316517,0.002359572,0.0009602752,0.0007085132,0.0008440997,0.0007719844,0.00134318,0.0001159906],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006292402,"about_ca_system_score_gemma":0.0006595342,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002705109,"about_ca_topic_score_gemma":0.0007800515,"domain_scores_codex":[0.9874406,0.008628652,0.00144323,0.001060022,0.001180692,0.0002468395],"domain_scores_gemma":[0.9445698,0.03020911,0.01749834,0.003397078,0.002585974,0.001739618],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1529213,0.001654198,0.7671614,0.002150512,0.02246855,0.0003930576,0.0002724103,0.001049009,0.01032269,0.0001305386,0.0008369843,0.04063923],"study_design_scores_gemma":[0.01635816,0.02787944,0.9407432,0.0001425366,0.008606168,0.0009225549,0.0001048399,0.0008528923,0.002442112,0.0001543606,0.001729007,0.00006470295],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831461,0.01365253,0.0009120731,0.0001706858,0.00003527851,0.0004580679,0.0007568746,0.00002807211,0.0008402667],"genre_scores_gemma":[0.9971968,0.0009248971,0.0004522569,0.0001696855,0.00004117742,0.00020533,0.0009153666,0.00000751475,0.00008698964],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0233627,"threshold_uncertainty_score":0.1235552,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}